US Pat. No. 10,137,080

METHOD OF STABILIZING ANTIBODY AND STABILIZED SOLUTION-TYPE ANTIBODY PREPARATION

KYOWA HAKKO KIRIN CO., LT...

1. A solution-type antibody preparation comprising an antibody, 10 to 30 mg/mL glycine, and 0.1 to 50 mmol/L citric acid, wherein the formation of soluble associations and chemically degraded products of said antibody are inhibited in said preparation,wherein said preparation has at least one of the following features (a) and (b):
(a) said preparation contains between 0.1 to 1 mg/mL of non-ionic surfactant; and
(b) said preparation does not contain polyethylene glycol.
US Pat. No. 10,138,361

RUBBER COMPOSITION AND PNEUMATIC TIRE

SUMITOMO RUBBER INDUSTRIE...

1. A rubber composition, comprising:5 to 150 parts by mass of carbon black;
10 to 150 parts by mass of silica, wherein the silica comprises silica (1) that has a nitrogen adsorption specific surface area in the range 50 m2/g to less than 120 m2/g and silica (2) that has a nitrogen adsorption specific surface area of 120 m2/g or more;
100 parts by mass of a rubber component comprising styrene butadiene rubber; and
5 to 50 parts by mass of a modified polymer obtained by modifying a styrene-butadiene copolymer, wherein the modified polymer contains a moiety -(A)-C(O)R1 in which R1 is —OR4 or —B—(CO)OR5, A and B being, independently, a divalent saturated or unsaturated hydrocarbon group and R4 and R5 being, independently, hydrogen or a divalent saturated or unsaturated hydrocarbon group, and wherein the modified polymer has a weight average molecular weight of from 1000 to 100,000,
wherein the rubber composition has a tan? peak temperature of ?20° C. or higher, a rubber hardness of from 63 to 75, and a tan? at 70° C. of from 0.15 to 0.45.
US Pat. No. 10,139,385

METHOD OF TRACING CHEMICAL QUANTITIES USING ENCAPSULATED FLUORESCENT DYES

Ecolab USA Inc., Napervi...

1. A method of treating wastewater comprising introducing into wastewater (a) an aluminum salt and (b) an encapsulated tracer comprising a capsule encapsulating a core, the core comprising a xanthene derivative selected from Rhodamine WT and Rhodamine B, and the capsule comprising a polyethhylene oxide-polypropylene oxide-polyethylene oxide (“PEO-PPO-PEO”) tri-block copolymer, the encapsulated tracer introduced into the wastewater in a dosage such that the amount of aluminum salt introduced to the wastewater can be determined from fluorescence of the xanthene derivative present in the encapsulated tracer, wherein the xanthene derivative and the PEO-PPO-PEO tri-block copolymer are present in the encapsulated tracer at a ratio of from 1:20 to 3:10 by weight, and the wastewater has a pH of 6 or less.
US Pat. No. 10,137,081

DEVICE AND METHOD FOR SUSTAINED RELEASE OF ANTIPSYCHOTIC MEDICATIONS

Delpor, Inc., San Franci...

1. A drug delivery device, comprising:a non-erodible, non-porous housing member defining a reservoir, said housing member having first and second opposing ends;
a porous partition positioned in the housing member; and
contained within said reservoir, a drug formulation comprised of a salt form of risperidone selected from the group consisting of risperidone octanoate, risperidone hexanoate and risperidone pentanoate, wherein the drug formulation when hydrated releases risperidone at a rate that provides a therapeutic dose over a period of at least about 2 months.
US Pat. No. 10,138,362

ETHYLENE-BASED POLYMER COMPOSITION FOR FILMS WITH IMPROVED TOUGHNESS

Dow Global Technologies L...

1. A composition comprising a first composition, comprising at least one ethylene-based polymer, and wherein the first composition comprises a MWCDI value greater than 1.2, and a melt index ratio (I10/I2) that meets the following equation: I10/I2?7.0?1.2×log (I2).
US Pat. No. 10,137,082

HYDROGEL MICROPARTICLE SCAFFOLD WITH GRADIENTS OF DEGRADABILITY AND METHODS THEREOF

Washington University, S...

1. A modular scaffold comprising a plurality of hydrogel microparticles, wherein the hydrogel microparticles are crosslinked together with at least some crosslinks having tunable rates of enzymatic degradation, wherein the crosslinks is the plasmin sensitive peptide sequence Ac-GCGGVRNGGK-NH2.
US Pat. No. 10,137,083

OPHTHALMIC PREPARATIONS

SGN Nanopharma Inc, Tamp...

1. An ophthalmic nanoemulsion formulation comprising:(a) a cyclosporine selected from the group consisting of cyclosporines A, B, C, D and G,
(b) ethanol,
(c) at least one oil, wherein the oil comprises medium chain triglycerides,
(d) at least one surfactant, wherein the surfactant is a polysorbate,
(e) at least one cationic preservative, and
(f) water or phosphate buffered saline,
wherein (i) the cyclosporine is in a solid particulate state and in a soluble state, (ii) the cyclosporine in the solid particulate state is present in the water or the phosphate buffered saline, (iii) the formulation is phospholipid-free, and (iv) the formulation comprises globules of oil comprising dissolved cyclosporine, wherein the globules have a mean diameter between 100 and 250 nm,
wherein the at least one cationic preservative is selected from the group consisting of cetyltrimethylammonium bromide, cetylpyridinium chloride, benzethonium chloride, and benzalkonium chloride.
US Pat. No. 10,137,595

WOOD TREATMENT FOR DIMENSIONAL STABILIZATION

Koppers Performance Chemi...

1. A method of treating a wood product comprising the steps of contacting a composition consisting essentially of polypropylene glycol or a polypropylene glycol copolymer with an average molecular weight of between at least 500 and 100,000 with a wood product, wherein the treated wood product has a retention of at least 5 pounds per cubic foot (pcf) of said polypropylene glycol or a polypropylene glycol copolymer, and wherein the treated wood product has improved dimensional stability compared to an untreated wood product.
US Pat. No. 10,138,364

THERMOPLASTIC MOLDING COMPOUNDS WITH OPTIMIZED FLOWABILITY-TOUGHNESS RATIO

INEOS STYROLUTION GROUP G...

1. A thermoplastic composition comprising the components A and B and optionally the further components C and D which altogether sum to 100 wt %, wherein the molding material is composed of:a) 60 to 75 wt % of one or more styrene copolymers A,
b) 25 to 40 wt % of one or more graft copolymers B,
c) 0 to 15 wt % of a rubber C distinct from component B,
d) 0 to 5 wt % of one or more additives D,
wherein the composition comprises 1.1 to 2.8 wt % based on the total weight of the components A to D, of oligomers, wherein the oligomers have a weight average molar mass Mw in the range from 100 to 700 g/mol and are formed substantially from styrene and/or acrylonitrile, and wherein the oligomers are formed from 2, 3, 4, 5 or 6 monomer units,
characterized in that the graft copolymer B is constructed from:
(B1): 40 to 85 wt %, based on the solids content of the graft copolymer B, of a graft substrate B1 obtainable by:
(a) polymerization of:
(B11): 0 to 10 wt %, based on the graft substrate B1, of styrene, and (B12): 90 to 100 wt %, based on the graft substrate B1, of butadiene,
and (b) agglomeration of the obtained graft substrate B1 by addition of:
(E): 0.01 to 5 parts by wt, based on 100 parts by wt of the graft substrate B1, in each case based on the solids content, of an agglomerating copolymer (E) composed of:
(E1): 80 to 99.9 wt % of one or more C1- to C12-alkyl acrylates or C1- to C12-alkyl methacrylates and
(E2): 0.1 to 20 wt % of one or more comonomers selected from the group consisting of acrylamide, methylacrylamide, ethylacrylamide and n-butylacrylamide; and
(B2): 15 to 60 wt %, based on the solids content of the graft copolymer B, of a graft shell (B2), obtainable by reaction of the agglomerated graft substrate B1 with a mixture of:
(B21): 70 to 90 wt %, based on the graft shell B2, of styrene, and
(B22): 10 to 30 wt %, based on the graft shell B2, of acrylonitrile,
wherein
(i) the agglomerating copolymer (E) has a polydispersity U of less than 0.27 and a d50 value of 100 to 150 nm and
(ii) the agglomerated graft substrate B1 has a bimodal particle size distribution of a fraction x) of nonagglomerated particles having a d50 value in the range from 80 to 120 nm and a fraction y) of agglomerated particles having a d50 value in the range from 350 to 550 nm and a polydispersity U of less than 0.27.
US Pat. No. 10,137,084

USE OF BETHANECHOL FOR TREATMENT OF XEROSTOMIA

Acacia Pharma Limited, C...

1. A method of treating xerostomia, comprising buccal administration of bethanechol to a subject in need thereof.
US Pat. No. 10,137,596

FLEXIBLE HIGH-DENSITY FIBERBOARD AND METHOD FOR MANUFACTURING THE SAME

1. A flexible high-density fiberboard essentially free of formaldehyde and isocyanates and comprising80 to 90% by weight of straw fibers, and
20 to 10% by weight of a thermoplastic elastomer, wherein the thermoplastic elastomer is a vinyl acetate-ethylene-vinyl ester copolymer, and
one or more optional additive(s).
US Pat. No. 10,140,418

SYSTEM AND METHOD FOR CLASSIFICATION OF PATIENTS

Quest Diagnostics Investm...

1. A system for classifying a biological test sample, including:a database populated with reference expression data, the reference expression data including expression levels of a plurality of molecules in a plurality of reference samples, the molecules including a set of marker molecules that includes any combination of 100 or more of the polynucleotides listed in Table 4, each reference sample having a pre-assigned value for each of one or more clinically significant variables;
at least one processor; and
at least one storage medium containing program instructions for execution by said processor, said program instructions causing said processor to execute the steps of:
accepting input expression data, the input expression data including a test vector of expression levels of the set of marker molecules in the biological test sample; and
passing the input expression data to one or more analysis programs, the analysis programs including at least one statistical classification program which has been trained to distinguish among said pre-assigned values on the basis of that part of the reference data corresponding to expression levels of the set of marker molecules; and
assigning one of said pre-assigned values to the test sample for at least one of said clinically significant variables using the statistical classification program,
wherein the one or more clinically significant variables is selected from the group including disease state, disease prognosis, and treatment response.
US Pat. No. 10,137,085

NANOEMULSION FOR TRANSDERMAL DELIVERY AND METHOD OF MAKING THE SAME

Nano and Advanced Materia...

1. A chemical formulation for preparing a nanoemulsion, comprising:isopropyl myristate;
polysorbate 80;
ethanol;
water; and
an active ingredient selected from the group consisting of Schisandrin B and epidermal growth factor;
wherein a weight ratio of the water to the ethanol plus isopropyl myristate and polysorbate 80 is in a range of 3:7 to 2:8 and the nanoemulsion is an oil in water nanoemulsion.
US Pat. No. 10,137,597

SPRAYED ARTICLE AND MAKING METHOD

SHIN-ETSU CHEMICAL CO., L...

1. A sprayed article consisting of a sprayed body of cylindrical or cup shape comprising a rare earth oxide and/or rare earth fluoride ceramic material and having a wall thickness of 0.5 to 5 mm and an inner diameter at its cylinder portion of 200 to 600 mm and a sprayed coating comprising a rare earth oxide and/or rare earth fluoride ceramic material formed on the inner circumferential surface of the cylinder portion of the sprayed body,wherein the cylinder portion of the sprayed article has an ID roundness of 0.25 mm or less and/or an OD roundness of 0.20 mm or less.
US Pat. No. 10,138,367

COPOLYMERS OF POLY(ETHYLENE-CO-ACRYLIC ACID) AND POLYDIORGANOSILOXANES

3M Innovative Properties ...

1. A composition comprising:a) a poly(ethylene-co-acrylic acid) copolymer and
b) 0.1 to 10 wt. % of the functional copolymer of a functional copolymer comprising a poly(ethylene-co-acrylic acid) segment and a covalently bound polydiorganosiloxane segment.
US Pat. No. 10,138,368

BLOCK COPOLYMER COMPOSITION AND ADHESIVE COMPOSITION

Asahi Kasei Kabushiki Kai...

1. A block copolymer composition comprising:(i) 50% by mass or more and 90% by mass or less of a component (a) that is a block copolymer comprising a polymer block (A) mainly comprising a vinyl aromatic monomer unit and a polymer block (B) mainly comprising a conjugated diene monomer unit, wherein the block copolymer has a weight average molecular weight of 30,000 or higher and 150,000 or lower,
(ii) a component (b-2) that is a block copolymer comprising a polymer block (A) mainly comprising a vinyl aromatic monomer unit and a polymer block (B) mainly comprising a conjugated diene monomer unit, wherein at a ratio of a weight average molecular weight of the block copolymer to the weight average molecular weight of the component (a) is 2.5 or more and less than 3.4,
(iii) a component (b-3) that is a block copolymer comprising a polymer block (A) mainly comprising a vinyl aromatic monomer unit and a polymer block (B) mainly comprising a conjugated diene monomer unit, wherein a ratio of a weight average molecular weight of the block copolymer to the weight average molecular weight of the component (a) is 3.4 or more and less than 4.5, and
(iv) optionally a component (b-1) that is a block copolymer comprising a polymer block (A) mainly comprising a vinyl aromatic monomer unit and a polymer block (B) mainly comprising a conjugated diene monomer unit, wherein a ratio of a weight average molecular weight of the block copolymer to the weight average molecular weight of the component (a) is 1.5 or more and less than 2.5,
wherein a content of the vinyl aromatic monomer unit in the component (a) and the components (b-1), (b-2) and (b-3) is 10 to 50% by mass based on a total amount of the component (a) and the components (b-1), (b-2) and (b-3),
a hydrogenation ratio in the conjugated diene monomer unit in the component (a) and the components (b-1), (b-2) and (b-3) is 20% by mass or more, and
a content of the components (b-1), (b-2) and (b-3) is 10% by mass or more and 50% by mass or less.
US Pat. No. 10,139,393

SYSTEMS AND METHODS FOR MONITORING OF BLOOD LACTATE AND TARGETING OF BLOOD LACTATE VIA NUTRITIONAL SUPPORT

RUN THEM SWEET LLC, San ...

1. A method of providing nutritional support to a human patient that is unconscious or comatose, the method comprising:identifying a patient having a blood lactate concentration less than about 2.0 mM, wherein the patient is a human patient that is unconscious or comatose and wherein the identifying comprises:
taking a blood sample from the patient;
analyzing the blood sample with a lactate analyzer and determining that a blood lactate concentration of the patient is less than about 2.0 mM; and
administering a nutritional support to the patient;
wherein the nutritional support comprises a gluconeogenic precursor and/or a monocarboxylate compound and the administration is effective to achieve a blood lactate concentration greater than about 2.0 mM in the patient.
US Pat. No. 10,137,601

EXTRUDED EXPANDED THERMOPLASTIC POLYURETHANE ELASTOMER BEAD AND PREPARATION METHOD THEREFOR

Miracll Chemicals Co., Lt...

1. An extruded expanded thermoplastic polyurethane elastomer bead, consisting essentially of the following components in parts by weight: 100 parts by weight of a thermoplastic polyurethane elastomer, 0.01-0.5 parts by weight of a foaming nucleating agent, and 0.01-0.2 parts by weight of an antioxidant wherein a Shore hardness of the thermoplastic polyurethane elastomer is 55A -95A.
US Pat. No. 10,138,370

POLYCARBONATE COMPOSITIONS HAVING IMPROVED ADHESION TO POLYURETHANE LAYERS

COVESTRO DEUTSCHLAND AG, ...

1. A composition comprising the following components:A) 30 to 45 parts by weight of at least one polymer selected from the group consisting of aromatic polycarbonate and aromatic polyester carbonate,
B) 32 to 54 parts by weight of at least one polyalkylene terephthalate,
C) 16 to 23 parts by weight of at least one mixture comprising at least one polybutadiene-based graft polymer and at least one butadiene-free vinyl (co)polymer,
D) 0.1 to 20.0 parts by weight (based in each case on the sum total of the components A to C) of at least one polymer additive,
where the polybutadiene content based on the sum total of the parts by weight of the components A to C is 8% to 18% by weight,
and where the total content of butadiene-free vinyl (co)polymer from the component C based on the sum total of the parts by weight of the components A to C is 3% to 12% by weight, and where the sum total of the parts by weight of the components A to C in the composition is normalized to 100.
US Pat. No. 10,139,395

METHOD FOR ACTIVATION OF HELPER T CELL AND COMPOSITION FOR USE IN THE METHOD

International Institute o...

1. A method for activating a helper T cell, comprising contacting an antigen-presenting cell with a WT1 peptide, and thereby activating the helper T cell, wherein:(a) the WT1 peptide has an ability to bind to an HLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule, and HLA-DPB1*0501 molecule, and wherein the WT1 peptide is
a peptide consisting of amino acid sequence: Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met His Ser Arg Lys His (SEQ ID NO: 2); and
(b) the antigen-presenting cell is positive for at least one molecule chosen from HLA-DRB1*1501, HLA-DPB1*0901, and HLA-DPB1*0501; and
(c) the helper T cell expresses a TCR-CD3 complex that recognizes a complex of a WT1 peptide and an HLA-molecule chosen from HLA-DRB1*1501, HLA-DPB1*0901, and HLA-DPB1*0501.
US Pat. No. 10,137,091

IMMEDIATE/DELAYED DRUG DELIVERY

UNIVERSITY OF STRATHCLYDE...

1. A press-coated tablet formulation for an immediate, followed by a delayed release of an active agent, the tablet comprising:(a) a core comprising an active agent together with an excipient(s); and
(b) a delayed release layer surrounding the core and comprising a wax and a low substituted hydroxypropyl cellulose in a ratio of 40:60 to 60:40 w/w; wherein the delayed release layer substantially delays release of the active agent within the core for between 3-8 hours after administration of the tablet to a subject and thereafter a pulsed release of the active agent from the core occurs, such that at least 70% of the active agent in the core is released within 5-45 minutes and wherein the low substituted hydroxypropyl cellulose is micronized with a mean particle diameter of 20 mm and has a molecular weight of 115,000 and a hydroxypropyl cellulose content of 8%; and
(c) a top-coating layer comprising a portion of an active agent together with one or more excipients wherein a substantially immediate pulsed release of the active agent occurs following administration to the subject of the tablet;
wherein the active agent in the core and on the top-coating layer is an NSAID.
US Pat. No. 10,138,117

AQUEOUS FORMULATIONS FOR REMOVING METAL HARD MASK AND POST-ETCH RESIDUE WITH CU/W COMPATIBILITY

Entegris, Inc., Billeric...

1. A composition for selectively removing titanium nitride and/or photoresist etch residue material from the surface of a microelectronic device having same thereon, said composition comprising at least one oxidizing agent, at least one etchant, at least one corrosion inhibitor, at least one passivating agent, at least one solvent, and optionally at least one complexing agent,wherein the oxidizing agent comprises a species selected from the group consisting of FeCl3 (both hydrated and unhydrated), Fe(NO3)3, Sr(NO3)2, CoF3, FeF3, MnF3, oxone (2KHSO5·KHSO4·K2SO4), periodic acid, iodic acid, vanadium (V) oxide, vanadium (IV,V) oxide, ammonium vanadate, ammonium peroxomonosulfate, ammonium chlorite (NH4ClO2), ammonium chlorate (NH4ClO3), ammonium iodate (NH4IO3), ammonium nitrate (NH4NO3), ammonium perborate (NH4BO3), ammonium perchlorate (NH4ClO4), ammonium periodate (NH4IO3), ammonium persulfate ((NH4)2S2O8), ammonium hypochlorite (NH4ClO), ammonium tungstate ((NH4)10H2(W2O7)), sodium persulfate (Na2S2O8), sodium hypochlorite (NaClO), sodium perborate, potassium iodate (KIO3), potassium permanganate (KMnO4), potassium persulfate, nitric acid (HNO3), potassium persulfate (K2S2O8), potassium hypochlorite (KClO), tetramethylammonium chlorite ((N(CH3)4)ClO2), tetramethylammonium chlorate ((N(CH3)4)ClO3), tetramethylammonium iodate ((N(CH3)4)IO3), tetramethylammonium perborate ((N(CH3)4)BO3), tetramethylammonium perchlorate ((N(CH3)4)ClO4), tetramethylammonium periodate ((N(CH3)4)IO4), tetramethylammonium persulfate ((N(CH3)4)S2O8), tetrabutylammonium peroxomonosulfate, peroxomonosulfuric acid, ferric nitrate (Fe(NO3)3), peracetic acid (CH3(CO)OOH), toluquinone, dimethyl-1,4-benzoquinone, chloranil, alloxan, and combinations thereof;
wherein the composition is substantially devoid of hydrogen peroxide, and
wherein the at least one corrosion inhibitor is selected from the group consisting of:
a species selected from the group consisting of pyridine-N-oxide, N-ethylmorpholine-N-oxide, N-methylpyrrolidine-N-oxide, and N-ethylpyrrolidine-N-oxide;
a heterocycle selected from the group consisting of quinoline, quinazoline, isoquinoline, pyrazine, quinoxaline, phenazine, phenanthridine, and acridine;
a heterocycle selected from the group consisting of quinolone, quinazoline, isoquinoline, pyrazine, quinoxaline, phenazine, phenanthridine, and acridine, the heterocycle comprising at least one substituent selected from the group consisting of phenyl, benzyl, phenethyl, 3-phenylpropyl, and benzyloxy.
US Pat. No. 10,138,374

LOW ENERGY, COLD PROCESS FORMULATION AID

Jeen International Corp.,...

1. An anhydrous cold process formulation aid in the form of a flake, slab, powder, a paste, a semi-solid, or a slurry consisting essentially of(i) a polymer having an aliphatic backbone selected from a polyquaternium polymer and a polymer having a plurality of pendant groups selected from alkali metal carboxylate groups and ammonium carboxylate groups, and
(ii) a wax selected from the group consisting of natural waxes and synthetic waxes, wherein if the wax is not micronized and is not self-emulsifying, the ratio, by weight, of the non-micronized wax to the polymer having an aliphatic backbone is from about 60:40 to 80:20, and if the wax is a micronized wax or a self-emulsifying wax, the ratio, by weight, of wax to polymer backbone is 70:30 to 98:2,
wherein when the anhydrous cold process formulation aid is mixed with an aqueous medium at a temperature not exceeding the melt point of the wax or the melt point of the cold process formulation aid, a hydrogel or an emulsion is formed.
US Pat. No. 10,139,398

METHODS AND COMBINATIONS OF SIGNALING MARKERS FOR ASSESSMENT OF DISEASE STATES

DEEPATH MEDICAL DIAGNOSTI...

4. A method of prognosticating leukemia relapse and guiding leukemia therapy in a leukemia subject having antibody treatment, comprising the steps:a) contacting a sample that contains a population of cells with one or more reagents that fixes and permeabilizes the sample, thereby producing a fixed and permeabilized cell population;
b) contacting the fixed and permeabilized cell population with a combination of antibodies that are directed to cellular biomarkers, wherein the antibodies are directed to at least three biomarkers and selected from anti-CD8a-144Nd, CD4-145Nd, CD20-147Sm, CD16-148Nd, CD45-154Sm, CD11c-159Tb, CD14-160Gd, CD33-166Er, CD24-168Er, CD3-170Er, CD66-171Yb, CD56-175Lu, CD27-152Sm, CD45RA-153Eu, IgD-161Dy, CD38-167Er, HLA-DR-174Yb, CD25-176Yb, IL3R/CD123-151Eu, CD19-156Gd, CD34-173Yb, CD117-169Tm, IL7R/CD127-158Gd, pp38MAPK-157Gd, total IKB -163Dy, pSTAT3-164Dy, pSTAT1-169Tm, pSTAT5-172Yb, and pPLCy2-173Yb, wherein the antibodies comprise anti- pp38 MAPK-157Gd and pSTAT5-172Yb; and
(c) identifying one or more subsets within the cell population having higher activities pSTAT5-172Yb and pp38 MAPK-157Gd, wherein the subset is associated with a cell type and is indicative of leukemia relapse or therapy responsiveness.
US Pat. No. 10,140,427

METHOD AND SYSTEM FOR ANALYSIS OF COMPOUNDS

Midas Mediscience Limited...

1. A compound analysis system, the system comprising:a micro-electrode array comprising a bio-compatible substrate, an isolated, living biological sample comprising an electrically active cellular network, and a plurality of electrodes, the array additionally comprising a plurality of electrically active channels as determined by said electrodes being in contact with cells of the electrically active cellular network;
a multi-channel amplifier coupled to said electrodes;
a processor and a memory operatively connected to said amplifier and operable to record changes in a plurality of features of the living biological sample in response to exposure to a compound, the plurality of features comprise spike speed and one or more other features comprising changes to the temporal and spatial pattern of recorded spikes, the processor and memory further operable to determine a multi-dimensional vector comprising one dimension for each of the plurality of features,
wherein said memory contains a library of vectors indicative of responses to known compounds and the processor and memory is further operable to compare the derived multi-dimensional vector to the library of vectors to identify the compound.
US Pat. No. 10,137,094

GASTRORETENTIVE DOSAGE SYSTEM AND PROCESS OF PREPARATION THEREOF

Sun Pharmaceutical Indust...

1. A gastroretentive capsule dosage system consisting of:(a) a shell filled with a powder consisting of an active ingredient, wherein the active ingredient is selected from the group consisting of acyclovir, gabapentin, pregabalin, trimetazidine, feropenem, carbidopa, levodopa, methyldopa, verapamil, propranolol, carvedilol, atenolol, albuterol, pirbuterol, nifedipine, nimodipine, nicardipine, amlodipine, prazosin, guanabenz, allopurinol, metoprolol, oxprenolol, baclofen, sumatriptan, benazepril, enalapril, lisinopril, captopril, quinapril, moxipril, indolapril, olindapril, retinapril, spirapril, cilazapril, perindopril, ramipril, zofenopril, fosinopril, nitrofurantoin, valacyclovir, azithromycin, inosine, didanosine, pranobex, tribavirin, vidarabine, simvastatin, pravastatin, atorvastatin, lovastatin, selegiline, midazolam, lithium carbonate, cimetidine, ranitidine, famotidine, nizatidine, bifentidine, nifentidine, roxatidine, omeprazole, lansoprazole, pantoprazole, antacids selected from magnesium carbonate, aluminum carbonate, aluminum hydroxide, magnesium oxide and sucralfate, carbenoloxalone, misoprostol, pirenzepine, telenzepine, bismuth salts, metronidazole, ciprofloxacin, clarithromycin, amoxicillin, cephalexin, ascorbic acid, folic acid, vitamin E, furosemide, topiramide, hydrochlorothiazide, orlistat and pharmaceutically acceptable salts, esters or prodrugs thereof; and
(b) an extended-release coating over the shell, wherein the extended-release coating is applied in an amount of 3% to 15% w/w based on the total weight of the dosage system and comprises one or more extended release polymer(s) selected from group consisting of cellulose acetate, ethylcellulose and copolymers of methacrylate/trimethyl aminoethyl methacrylate, and the extended-release coating optionally comprises one or more coating additive(s), said additives being selected from the group consisting of fillers, plasticizers, opacifiers, coloring agents, lubricants/glidants and mixtures thereof.
US Pat. No. 10,138,375

METHOD FOR MANUFACTURING ASPHALTIC SHEET MATERIALS INCLUDING EXPANDABLE GRAPHITE

Firestone Building Produc...

1. A method for producing an asphaltic sheet, the method comprising:(i) preparing an asphaltic masterbatch including an asphalt binder at a first temperature;
(ii) cooling the asphaltic masterbatch to a second temperature, where the second temperature is lower than the first temperature;
(iii) adding, after said step of cooling, a concentrate including expandable graphite to form an asphaltic composition including an expandable graphite concentrate; and
(iv) fabricating an asphaltic sheet from the asphaltic composition including an expandable graphite concentrate by submerging a reinforcing textile into the asphaltic composition including an expandable graphite concentrate.
US Pat. No. 10,139,399

METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY

Horizon Pharma Rheumatolo...

1. A method of treating a patient suffering from gout having a serum uric acid (SUA) level of 6 mg/dl or less, and reducing the incidence of infusion reaction in said patient, the method comprising:administering to said patient, a therapeutically effective amount of a PEGylated uricase every two weeks;
after a first period of time, determining the SUA level of said patient, and
if said SUA level of the patient is maintained below 6 mg/dl, continuing said administration of PEGylated uricase every two weeks, whereas if said SUA level of the patient is above 6 mg/dl, discontinuing said administration thereby reducing the incidence of infusion reaction in said patient, wherein said patient previously received ineffective allopurinol therapy or has a medical history in which allopurinol therapy is contraindicated.
US Pat. No. 10,137,095

USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY

GW Pharma Limited, Visio...

1. A method of reducing drop seizure frequency in a patient with Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) ?9-tetrahydrocannabinol (THC); and wherein the dose of the CBD is about 20 mg/kg/day.
US Pat. No. 10,138,376

REDUCED TRACKING, REDUCED CURING TIME ASPHALT EMULSION AND METHOD OF MAKING AND USING SAME

TexTile Rubber and Chemic...

1. An emulsion comprising:a continuous phase comprising water; and
a discontinuous phase comprising an asphalt composition and a vinyl acetate-ethylene (“VAE”) copolymer, wherein the vinyl acetate-ethylene copolymer comprises about 60% to about 95% by weight vinyl acetate monomers and about 5% to about 40% by weight ethylene monomers and wherein when the emulsion is cured, the cured asphalt composition has a penetration value of about 50 dmm to about 100 dmm and wherein the asphalt composition has a softening point of about 118 to less than 140° F.
US Pat. No. 10,137,096

BINGE BEHAVIOR REGULATORS

1. A method of regulating consumption of an alcoholic beverage, the method comprising administering to a subject in need thereof the compound 5-methoxy-2-aminoindan,thereby regulating the consumption of an alcoholic beverage.
US Pat. No. 10,138,377

LIGNIN DERIVATIVE, LIGNIN RESIN COMPOSITION, RUBBER COMPOSITION, AND MOLDING MATERIAL

SUMITOMO BAKELITE CO., LT...

1. A lignin derivative extracted from biomass and used for rubber reinforcement or for use in a molding material, the lignin derivative containing a soluble component in a polar organic solvent in an amount of 95% by mass or more and an insoluble component in a polar organic solvent in an amount of 1 to 5% by mass, and the soluble component having a number average molecular weight of 300 to 2,000.
US Pat. No. 10,139,401

METHOD FOR CAPTURING TARGET SUBSTANCE, SOLID-PHASE CARRIER FOR CAPTURING TARGET SUBSTANCE, AND METHOD FOR PRODUCING SOLID-PHASE CARRIER

JSR CORPORATION, Minato-...

1. A method for capturing a target substance, comprising:preparing a solid-phase carrier for capturing a target substance, the carrier having a base material which is a particle having a particle diameter of from 0.5 to 10 ?m, at least a portion of the surface thereof being formed of or coated with a saccharide, and having a linker comprising a polyalkylene glycol chain in a structure thereof and having a reactive functional group for binding a lipophilic ligand that specifically binds to the target substance and that has a Log P value of 0 or more, the Log P value being a log value of an octanol/water partition coefficient, wherein the number of atoms of the linker is 20-100, provided that the number of atoms of the linker is the number of atoms when the lipophilic ligand is bound to the linker and is the number of atoms counted from a starting point at the atom adjacent to the saccharide ring structure to an end point at the reactive functional group to be used for the binding of the lipophilic ligand, and that when the linker has a ring structure or the linker has a branched chain structure and has plural starting points and/or end points, the number of atoms of the linker is the minimum number of atoms from the starting point to the end point, and the saccharide is chemically bound to the linker;
binding the lipophilic ligand to the solid-phase carrier to obtain a solid-phase carrier having a ligand bound thereto; and
bringing the solid-phase carrier having the ligand bound thereto into contact with a sample possibly containing the target substance that specifically binds to the lipophilic ligand.
US Pat. No. 10,137,609

METHOD AND DEVICE FOR THE THERMAL TREATMENT OF FRICTION LININGS

TMD Friction Services Gmb...

1. A method for thermally treating friction linings, comprising:emitting IR radiation with wavelength(s) in the range of 2260 nm to 3000 nm from one or more IR radiation sources comprising one or more ceramic IR radiators or ceramic IR heating fields that generate IR radiation with a maximum radiation power in the wavelength range from 2260 nm to 3000 nm;
directing the IR radiation onto a friction lining body for a duration of 300 seconds to 2400 seconds to heat the friction lining body, wherein the friction lining body has a top surface and a surface opposite the top surface and defines a thickness between the top surface and the opposite surface, and wherein the heating directs IR radiation from the one or more IR radiation sources onto the top surface of the friction lining body; and
detecting a surface temperature of the friction lining body for controlling the one or more IR radiation sources to maintain a desired temperature of the friction lining body top surface and opposite surface, wherein following the heating for the duration of 300 to 2400 seconds the desired temperature of the top surface of the friction lining body is in the range from 300° C. to 500° C. (572° F. to 932° F.), and the desired temperature of the opposite surface of the friction lining body is at least 300° C. (572° F.).
US Pat. No. 10,138,121

HYDROGEN DOSAGE IN LED LIGHTING BULBS

SAES GETTERS, S.p.A., La...

1. A method for irreversible generation and dosage of hydrogen in a LED light bulb, the method comprising:heating an irreversible hydrogen dispenser comprising an active material for hydrogen release, wherein said active material for hydrogen release is:
at least one material A selected from the group consisting of LiH, NaH, MgH2, CaH2, LiAlH4, LiBH4, NaAlH4, their sub-stoichiometric compounds comprising at least one third of the hydrogen amount comprised in the corresponding stoichiometric compounds, and mixtures thereof; or
a mixture between:
at least one material B selected from the group consisting of TiH2, ZrH4, YH2, ZrCr(2?x)Mn(x)H2, LaNi(5?y)AlyH(6+z), LaNi(5?y)SnyH(6+z), and their sub-stoichiometric compounds comprising at least one third of the hydrogen amount comprised in the corresponding stoichiometric compounds, wherein x is comprised between 0 and 2, y is comprised between 0 and 0.25, and z is comprised between 0 and 0.5; and
at least one material selected from the group consisting of material A and material C, wherein material C is at least one selected from the group consisting of Al, Sn, AlNi, AlSi, CuAl, and CuSn,
wherein a sum of WA+WB is at least 5 mg/dm3 of the LED light bulb volume and a ratio WB/(WA+9*WC) is comprised between 0 and 0.8, where WA is a weight of materials A in mg/dm3 of the LED light bulb volume, WB is a weight of materials B in mg/dm3 of the LED light bulb volume, and WC is a weight of materials C in mg/dm3 of the LED light bulb volume.
US Pat. No. 10,138,378

PLASMA GAS THROAT ASSEMBLY AND METHOD

MONOLITH MATERIALS, INC.,...

1. A method of making carbon black comprising:flowing a plasma gas into a plasma forming region and forming a plasma;
flowing the plasma gas through a throat which is connected to the plasma forming region and a carbon black forming region, wherein the throat is narrower than the plasma forming region, causing the plasma gas to accelerate and create, maintain or increase turbulence within the throat; and
injecting carbon black forming feedstock comprising methane upstream of or into the throat, resulting in carbon black with increased surface area as compared to carbon black formed without the feedstock injection upstream of or into the throat.
US Pat. No. 10,139,402

SEPARATION METHOD, DETECTION METHOD, SIGNAL MEASUREMENT METHOD, METHOD FOR DETERMINING DISEASE, METHOD FOR EVALUATING DRUG EFFICACY OF DISEASE TREATMENT DRUG, KIT, AND LIQUID COMPOSITION

JSR CORPORATION, Minato-...

1. A method for separating a vesicle having a lipid bilayer membrane from a biological sample, the method comprising:forming a complex of a vesicle and a solid phase carrier by bringing the biological sample comprising the vesicle having the lipid bilayer membrane into contact with the solid phase carrier to which a ligand for recognizing a surface antigen present on a surface of the vesicle and is bound, and
washing the complex,
wherein the forming and the washing is performed in the presence of a nonionic surfactant to reduce an aggregation of the complex,
wherein the nonionic surfactant is one or more selected from the group consisting of a polyalkylene glycol ethylene oxide adduct, a fatty acid ester of sorbitan, a fatty acid ester of sorbitol, an ethylene oxide adduct of sorbitan fatty acid ester, and an ethylene oxide adduct of sorbitol fatty acid ester.
US Pat. No. 10,137,098

TRANSDERMAL PREPARATION

TEIKOKU SEIYAKU CO., LTD....

1. A transdermal absorption preparation comprising:silodosin or a salt thereof, or tamsulosin or a salt thereof as an active ingredient,
an acrylic pressure-sensitive adhesive that comprises a copolymer of at least one (meth)acrylic acid monomer and at least one vinyl monomer and that contains a carboxyl group, and
at least one transdermal absorption promoting agent selected from the group consisting of oleyl alcohol, lauryl alcohol, and lauromacrogol,
wherein the vinyl monomer comprises at least one selected from the group consisting of vinyl acetate, N-vinyl-2-pyrrolidone, acrylamide, dimethylacrylamide, diethylacrylamide, methacrylamide, N-methylolacrylamide, glycidyl acrylate, and glycidyl methacrylate, and
wherein the transdermal absorption preparation does not include fatty acid ester and/or fatty acid amide.
US Pat. No. 10,138,379

N-HALAMINES COMPOUNDS AS MULTIFUNCTIONAL ADDITIVES

Board of Regents, The Uni...

1. A method of making a rechargeable antimicrobial anti-biofilm article comprising the steps of:adding one or more substituted hydantoins to a target material, wherein the one or more substituted hydantoins are selected from the group consisting of 1-chloro-3-ethyl-5,5-dimethylhydantoins, 1-chloro-3-dodecyl-5,5-dimethylhydantoin, 1-chloro-3-octadecyl-5,5-dimethylhydantoin, 1-chloro-3-docosyl-5,5-dimethylhydantoin, and mixtures thereof; and
forming a rechargeable antimicrobial anti-biofilm article from the target.
US Pat. No. 10,137,099

ACTIVATION OF AMP-PROTEIN ACTIVATED KINASE BY OXALOACETATE COMPOUNDS

8. An exercise-substitutive method comprising a step of administering to a subject in need thereof an effective amount of oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate or aspartate.
US Pat. No. 10,138,123

METHOD FOR REGENERATING WORKING SOLUTION USED FOR PRODUCTION OF HYDROGEN PEROXIDE AND METHOD FOR PRODUCING HYDROGEN PEROXIDE USING REGENERATED WORKING SOLUTION

MITSUBISHI GAS CHEMICAL C...

1. A process for regeneration of a working solution provided for continuous use in the production of hydrogen peroxide via an anthraquinone process, the process comprising:distilling the working solution to separate organic solvent components containing an alcohol and the ketone form of the alcohol; and
subjecting resulting organic solvent components to hydrogenation treatment in the presence of a metal catalyst to regenerate the ketone form back into the original alcohol.
US Pat. No. 10,138,380

WATER/OIL REPELLANT COATING FILM AND MANUFACTURING METHOD THEREOF

National Institute of Adv...

1. A water/oil repellant coating film formed on a surface of a solid object water/oil repellant coating film comprising:a three-dimensional crosslinking structure formed only by siloxane bonds, wherein the three-dimensional crosslinking structure of the water/oil repellant coating film is terminated with functional groups selected from a group consisting of a methyl group, an alkoxy group and a hydroxyl group in combination thereof, and
a mole ratio of alkoxy groups and hydroxyl groups with respect to the methyl groups existing on the surface of the water/oil repellant coating film is equal to or less than 0.1, wherein
a root mean square surface roughness Rq of the water/oil repellant coating film is equal to or less than 50 nm.
US Pat. No. 10,137,100

ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACH

The Regents of the Univer...

1. A method of treating shock in a mammal in need thereof comprising orally administering to the mammal a therapeutically effective amount of an aqueous pharmaceutical composition comprising: (i) tranexamic acid, (ii) polyethylene glycol-3350, and (iii) electrolytes.
US Pat. No. 10,138,124

TREATING SULFURIC ACID

ROHM AND HAAS COMPANY, C...

1. A method for treating sulfuric acid comprising the step (I) of bringing said sulfuric acid into contact with a collection of solid particles (B) having BET surface area of 50 m2/g to 5,000 m2/g and having volume-average particle diameter of 200 ?m or less.
US Pat. No. 10,138,381

HIGH PERFORMANCE SILICON BASED THERMAL COATING COMPOSITIONS

Burning Bush Group, LLC, ...

1. A silicon based coating composition, comprising:a. 1% to 99% (w/w) of a first mixture, by weight of the total composition, comprising:
i. 60% to 70% (w/w of the first mixture) polysilazane;
ii. 12% to 22% (w/w of the first mixture) polysiloxane; and
iii. 12% to 22% (w/w of the first mixture) polysilane; and
b. 1% to 99% (w/w) of a second mixture, by weight of the total composition, comprising:
i. 77% to 87% (w/w of the second mixture) high temperature silicone based resin with a heat resistance up to 1200 ° F.;
ii. 7% to 17% (w/w of the second mixture) organic solvent;
iii. 1% to 5% (w/w of the second mixture) ceramic microspheres; and
iv. 1% to 5% (w/w of the second mixture) corrosion inhibitor;which composition after curing is a thermal barrier coat composition that can withstand temperature over 1600° F. in accordance with ASTM E1530 test standards for heat stability, having a thickness ranging between about 0.4 mil and about 1.5 mil and a hardness ranging between about 4H and about 9H.
US Pat. No. 10,139,405

SYSTEM FOR DETECTING INFECTION IN SYNOVIAL FLUID

CD Diagnostics, Inc., Cl...

1. A method of treating joint pain in a subject, the method comprising;applying a fluid sample obtained from the joint to a system comprising a device, cartridge or strip having a flow path through which a fluid sample can move, the flow path comprising:
a) a first region comprising a first detection reagent that specifically binds a human neutrophil ?-defensin; and
b) a second region comprising an internal control detector reagent; and
treating the subject with an anti-bacterial agent if greater than 5,000 ng/ml of human neutrophil ?-defensin is detected in the fluid sample, or treating the subject for aseptic-inflammation if less than 5,000 ng/ml of human neutrophil ?-defensin is detected in the fluid sample.
US Pat. No. 10,137,101

ALKYLAMIDO COMPOUNDS AND USES THEREOF

Nogra Pharma Limited, Du...

1. A method of treating acne in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl-(S)-3-(4-aminophenyl)-2-methoxypropionic acid, or a pharmaceutically acceptable salt or a pharmaceutically acceptable N-oxide thereof.
US Pat. No. 10,138,382

FORMULATIONS COMPRISING METAL NANOWIRES AND PEDOT

1. A composition comprisingi) particles comprising a conductive polymer, wherein the particles comprising the conductive polymer comprise a complex of poly(3,4-ethylenedioxythiophene) and polystyrene sulfonic acid (PEDOT:PSS),
ii) metal nanowires, and
iii) at least one solvent,
wherein each of the following conditions are satisfied:
?1) the particles comprising the conductive polymer are characterized by a weight average particle diameter of less than 60 nm;
?2) the content of cations of the metal on which the metal nanowires ii) are based is below 500 ppm, based on the total weight of the composition; and
?3) the composition comprises, in addition to component iii), at least one high-boiling solvent that is miscible with the at least one solvent iii) and that has a boiling point (determined at 1013 mbar) of more than 100° C.
US Pat. No. 10,138,126

SIMPLE PRODUCTION METHOD FOR GRAPHENE BY MICROORGANISMS

1. A method of aerobically producing graphene from graphene oxide with a microorganism comprising:a) growing one or more microorganism cultures in suitable media under aerobic conditions;
b) reducing concentration of the one or more cultures between approximately 102 CFU/mL to approximately 1010 CFU/mL, wherein said reduced concentration comprises transferring a portion of the culture to a vessel;
c) adding graphene oxide to the vessel under atmospheric conditions;
d) removing the added graphene oxide from the vessel after a predetermined time, wherein said removed graphene oxide contains graphene; and
e) washing the removed graphene oxide with a solution and recovering the graphene, wherein the yield of recovered graphene is greater than 50% of the added graphene oxide;
wherein the one or more microorganism cultures is selected from the group consisting of: Pseudomonas aeruginosa, Candida albicans, Streptococcus faecalis, Staphylococcus aureus, algae, cyanobacteria, and combinations thereof,
wherein the microorganism reduces graphene oxide to graphene.
US Pat. No. 10,138,383

ANTI-FOGGING COATING COMPOSITION, AND ANTI-FOGGING FILM AND TRANSPARENT ARTICLE USING THE SAME

1. An anti-fogging coating composition comprising:a dopamine;
a hydrophilic polymer;
a plurality of inorganic oxide particles; and
a solvent.
US Pat. No. 10,139,407

METHODS FOR DETECTING BACTERIA USING POLYMER MATERIALS

Universiteit Maastricht, ...

1. A method for characterizing bacteria, the method comprising:passing a buffer over and in contact with an imprinted polymer on a substrate;
detecting a first temperature of the substrate;
passing a liquid containing an analyte comprising a first bacteria and a second bacteria over and in contact with the imprinted polymer on the substrate, the imprinted polymer formulated to bind to the first bacteria, wherein a heat transfer property of the imprinted polymer varies based on an amount of the analyte bound thereto, and wherein the first bacteria binds to the imprinted polymer with a higher affinity than the second bacteria;
binding a portion of the first bacteria and the second bacteria of the analyte to the imprinted polymer;
removing at least a portion of the second bacteria from the imprinted polymer;
detecting a second temperature of the substrate; and
calculating a concentration of the first bacteria in the liquid based on the first temperature and the second temperature of the substrate.
US Pat. No. 10,138,384

OPHTHALMIC AND CONTACT LENS SOLUTIONS USING BICINE

FXS Ventures, LLC, Salem...

1. An ophthalmic product comprising:at least one contact lens;
a contact lens container; and
a sufficient volume of a contact lens solution to wet the contact lens where the contact lens solution comprises 0.001 to about 5 weight percent of bicine; an effective amount of biologically compatible buffer to maintain the pH of the solution between 5.5 and 8.5 pH; and the balance water.
US Pat. No. 10,139,408

METHOD FOR DIAGNOSTICS, TREATMENT AND PREVENTION OF PARKINSON'S DISEASE

NeuroInnovation Oy, (FI)...

1. A method for measuring the probability of a subject developing or having Parkinson's disease (PD) characterized by a prodromal and premotor period in which the subject has no motor symptoms, the method comprisinga) obtaining a fecal sample from the subject;
b) measuring the abundances of at least Prevotellaceae bacteria in the sample; and
c) determining the probability of the subject developing or having PD based on the abundances measured in step b),
wherein a high abundance of said Prevotellaceae in relation to other bacteria in the sample indicates a low probability of the subject developing or having PD.
US Pat. No. 10,137,104

COMBINATION THERAPY WITH AN ANTI-HYALURONAN AGENT AND THERAPEUTIC AGENT

Halozyme, Inc., San Dieg...

1. A method for treating pancreatic cancer, comprising administering to a subject:a) a composition comprising a soluble PH20 hyaluronidase, wherein the soluble PH20 hyaluronidase is PEGylated; and
b) a composition comprising a tumor-targeted taxane that is nab-paclitaxel or nab-docetaxel, wherein:
the subject has pancreatic cancer;
the soluble PH20 hyaluronidase comprises a sequence of amino acid residues that has at least 95% sequence identity to the sequence of amino acid residues set forth in SEQ ID NO: 4; and
the composition comprising the PEGylated soluble PH20 hyaluronidase, and the composition comprising the tumor-targeted taxane are administered separately in two compositions or are administered in a single composition.
US Pat. No. 10,138,386

METHOD OF INKJET PRINTING A COLORLESS INK

EASTMAN KODAK COMPANY, R...

1. A method of inkjet printing, comprising:providing a substrate having a predetermined area for imaging,
providing a colored image on the substrate, the colored image comprising colored areas and non-colored areas on the substrate, and
ink jetting an aqueous colorless inkjet ink composition as printing colorless drops to provide a colorless image over at least 50% of the colored areas of the colored image and over a predetermined areal percentage of the non-colored areas of the colored image,
wherein the aqueous colorless inkjet ink composition is visible colorant-free and non-UV curable, has a viscosity of less than 5 centipoises (0.005 N-sec) at 25° C., and comprises an anionic polyether polyurethane having an acid number of at least 50 and an anionic acrylic polymer or anionic styrene-acrylic polymer having an acid number of at least 50; the weight ratio of the anionic polyether polyurethane to the anionic acrylic polymer or anionic styrene-acrylic polymer is from 1:9 to and including 9:1; and the total amount of the anionic polyether polyurethane and the anionic acrylic polymer or anionic styrene-acrylic polymer is less than or equal to 20 weight % based on the total aqueous colorless inkjet ink composition weight,
wherein:
either the aqueous colorless inkjet ink composition is ink jetted as printing colorless drops to increase glossiness of the colored areas of the colored image by at least 3 gloss units compared to the glossiness of the colored areas of the colored image without the aqueous colorless inkjet ink composition, as measured by a 75° glossmeter, or
the aqueous colorless inkjet ink composition is ink jetted as printing colorless drops to increase glossiness of the non-colored areas of the colored image by at least 3 gloss units compared to the glossiness of the non-colored areas of the colored image without the aqueous colorless inkjet ink composition, as measured by a 75° glossmeter, and
the aqueous colorless inkjet ink composition comprises a mixture of at least one anionic acrylic polymer or anionic styrene-acrylic polymer having a molecular weight of at least 2,000 Daltons and up to and including 10,000 Daltons, and at least one other anionic acrylic polymer or anionic styrene-acrylic polymer having a molecular weight greater than 10,000 Daltons.
US Pat. No. 10,139,410

PROTEIN-PROTEIN INTERACTION AS BIOMARKERS

H. LEE MOFFITT CANCER CEN...

1. A method for treating a malignancy in a subject, comprising administering a protein-protein interaction (PPI) inhibitor or inducer to the subject, wherein the subject is predetermined to have two or more target binding partners of a cancer cell signaling network that are detected by proximity ligation assay (PLA), wherein the target binding partners are selected from among the following pairs of binding pairs tyrosine-protein kinase Met (MET) and growth factor receptor-bound protein 2 (Grb2); epidermal growth factor receptor (EGFR) and GRB2 associated binding protein 2 (GAB2); and tyrosine-protein kinase Met (MET) and another binding partner of MET; and wherein the PPI inhibitor or inducer inhibits or induces protein-protein interaction between the two or more target binding partners.
US Pat. No. 10,137,106

COMPOSITIONS AND METHODS TO TREAT NIEMANN-PICK DISEASE

Cognitive Research Enterp...

1. A method for treating Niemann-Pick Type C (NPC) in a subject in need of treatment, comprising administering to the subject a composition comprising bryostatin-1 in an effective amount to treat NPC, wherein the effective amount results in a blood plasma concentration of bryostatin-1 of about 0.5 nM to about 7.5 nM.
US Pat. No. 10,138,131

STRUCTURE DIRECTING AGENT FOR IMPROVED SYNTHESIS OF ZEOLITES

SACHEM, INC., Austin, TX...

1. A method of preparing a SSZ-39 AEI zeolite, comprising:providing a precursor for 3,5-dimethyl-N,N-dimethylpiperidinium hydroxide;
treating the precursor to provide an intermediate 3,5-dimethyl-N,N-dimethylpiperidinium salt that, when subsequently treated to form the 3,5-dimethyl-N,N-dimethylpiperidinium hydroxide, has a content of trans isomer of the 3,5-dimethyl-N,N-dimethylpiperidinium hydroxide in a range from greater than 25% up to 80% and a content of the cis isomer from less than 75% to 20%;
contacting under crystallization conditions a mixture of sources of an oxide of silicon and faujasite, one or more alkali metal hydroxide or alkaline earth metal hydroxide, water, and a structure-directing agent comprising the 3,5-dimethyl-N,N -dimethylpiperidinium hydroxide having the content of the trans isomer of the 3,5-dimethyl-N,N-dimethylpiperidinium hydroxide in the range from greater than 25% up to 80% and a content of the cis isomer from less than 75% down to 20%; and
calcining the mixture to form a SSZ-39 AEI zeolite,
wherein the precursor is 3,5-dimethyl pyridine, or N-methyl-3,5-dimethylpiperidine, or 3,5-dimethylpiperidine.
US Pat. No. 10,139,412

SEMAPHORIN 3A AS A DIAGNOSTIC MARKER FOR UROTHELIAL CANCER

Technion Research and Dev...

1. A method for determining efficacy of a treatment for a urothelial cancer in a subject in need thereof, said method comprising:a) determining the levels of Semaphorin 3A in a first urine cytology sample of said subject;
b) treating said subject with an anticancer treatment;
c) determining the levels of Semaphorin 3A in a second urine cytology sample of said subject; and
d) comparing the levels of Semaphorin 3A in said first and second urine cytology samples,
wherein a decrease in Semaphorin 3A levels from the first to the second urine cytology sample is indicative of said treatment being efficacious.
US Pat. No. 10,136,596

INBRED CORN LINE KW6D1334

KWS SAAT SE, Einbeck (DE...

1. A seed of inbred corn line designated KW6D1334, wherein a representative sample of seed of said line was deposited under ATCC Accession No. PTA-124036.
US Pat. No. 10,137,108

NUTRITIONAL COMPOSITION USEFUL IN THE TREATMENT OF IBD PATIENTS

Nestec S.A., Vevey (CH)

1. A method for achieving a result selected from the group consisting of treatment of inflammatory bowel disease (IBD), prolonging remission of IBD, and maintaining or improving the mucosa health status of a patient having IBD or in remission from IBD, the method comprising:administering a composition comprising (a) free form amino acids comprising 9.0-11.0 g threonine in free form/100 g of the composition, 7.0-10.0 g serine in free form/100 g of the composition, and 7.0-9.0 g proline in free form/100 g of the composition; (b) carbohydrates and proteins comprising whey TGF-Beta; and (c) at least one essential fatty acid to the patient,
the carbohydrates are 10-50 energy percent of the composition, total proteins comprising the free form amino acids and the proteins comprising the whey TGF-Beta are 30-60 energy percent of the composition, and fats comprising the at least one essential fatty acid are 10-40 energy percent of the composition,
the patient has initiated therapy comprising at least one of infliximab or adalimumab at least 12 weeks prior to initiating the administering of the composition to the patient.
US Pat. No. 10,138,389

AQUEOUS REACTION LIQUID COMPOSITION, INK SET COMPRISING SUCH AQUEOUS REACTION LIQUID COMPOSITION AND METHOD OF PRINTING USING SUCH AQUEOUS REACTION LIQUID COMPOSITION

1. An aqueous reaction liquid composition, comprising:a metal salt;
a first surfactant being an amphoteric surfactant; and
a second surfactant being a non-ionic surfactant.
US Pat. No. 10,139,413

MEANS AND METHODS FOR DIAGNOSING PANCREATIC CANCER IN A SUBJECT BASED ON A METABOLITE PANEL

METANOMICS HEALTH GMBH, ...

1. A method for treating a subject in need of a pancreas cancer therapy, comprising:(a) obtaining a sample of a subject suspected to suffer from pancreas cancer, wherein said sample is a blood, plasma, or serum sample, and then subjecting the sample to total lipids extraction;
(b) determining, using mass spectrometry, from the sample of step (a) the amounts of a group of biomarkers said group comprising (i) at least the biomarkers of one of the combinations shown in Table 1a, wherein the sphingomyelin(s), ceramide(s), and/or phosphorylated sphingobase(s) of Table 1a is/are selected from Table 1b or comprising (ii) at least the biomarkers shown in any one of Tables 17 to 26;
(c) comparing the said amounts of the biomarkers with references, whereby pancreas cancer is diagnosed;
(d) identifying a subject in need of a pancreas cancer therapy if said subject is diagnosed to suffer from pancreas cancer; and
(e) treating the subject with a cancer therapy selected from the group consisting of surgery, radiotherapy, or drug treatment.
US Pat. No. 10,136,597

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH288975

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH288975, produced by crossing a first plant of variety CV753235 with a second plant of variety CV747050, wherein representative seeds of said varieties CV753235 and CV747050 are deposited under ATCC Accession Nos. PTA-124506 and PTA-123816, respectively.
US Pat. No. 10,138,390

MODIFIED NANO-SILICA AND METHOD FOR PREPARING THE SAME, PIGMENT DISPERSION AND PHOTOSENSITIVE RESIN COMPOSITION

BOE TECHNOLOGY GROUP CO.,...

1. A pigment dispersion, characterized in that the pigment dispersion is prepared by dispersing a solute in a solvent and inducing a crosslinking reaction therein, and the average particle size of the solid particles in the pigment dispersion ranges from 40 nm to 100 nm; andthe solute comprises: based on 100% by mass of the pigment dispersion, 1% to 5% of modified nano-silica particles which have unsaturated double bonds grafted on the surface thereof and have an average particle size in the range of 5 nm to 50 nm, 3% to 6% of a dispersant, 2% to 6% of a binder resin, 10% to 20% of pigment, and 0.1% to 0.5% of a photoinitiator.
US Pat. No. 10,139,414

TN-MUC4 BINDING POLYPEPTIDES AND USES THEREOF

GO THERAPEUTICS, INC., C...

1. A Tn-MUC4 binding polypeptide comprising the six complementarity determining regions (CDRs) of the monoclonal antibody produced by the cell line 6E3 deposited with the European Collection of Authenticated Cell Cultures (ECACC) under accession number 09120103.
US Pat. No. 10,136,598

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH887497

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH887497, produced by crossing a first plant of variety CV752112 with a second plant of variety CV093813, wherein representative seeds of said varieties CV752112 and CV093813 are deposited under ATCC Accession Nos. PTA-124504 and PTA-123818, respectively.
US Pat. No. 10,139,415

METHOD FOR PREDICTING RESPONSIVENESS TO COMPOUND INHIBITING MAPK SIGNAL TRANSDUCTION PATHWAY

DAIICHI SANKYO COMPANY, L...

1. A method of treating a cancer disease, comprising:using a biological sample derived from a cancer patient,
measuring whether ?-catenin contained in the biological sample has at least one kind of a mutation selected from the group consisting of (i) an active mutation and (ii) a substitution mutation of an asparagine residue to a serine residue at position 287;
selecting a patient who is detected to have the mutation in ?-catenin as a patient to be subjected to cancer disease treatment with a means for inhibiting MEK1/2, wherein the patient has a cancer disease selected from colorectal cancer, skin cancer, lung cancer, or adrenal cortex cancer; and
administering a therapeutically effective amount of the means for inhibiting MEK1/2 to the selected patient.
US Pat. No. 10,136,599

COTTON VARIETY 15R535B2XF

Monsanto Technology LLC, ...

1. A plant of cotton variety 15R535B2XF, wherein a sample of seed of said variety has been deposited under ATCC Accession No. PTA-125091.
US Pat. No. 10,137,111

DRUG COMPOSITIONS COMPRISING AN ANTI-PARASITIC AND PROTON PUMP INHIBITOR

Adamis Pharmaceuticals Co...

1. A composition including:a paste including about 22% w/v omeprazole, about 30% w/v fenbendazole, and a wetting agent formulated in a melted polyethylene glycol base agent for oral administration to a mammal.
US Pat. No. 10,136,600

WHEAT CULTIVAR FA9S10-0038R

Monsanto Technology LLC, ...

1. A plant of wheat cultivar FA9S10-0038R, wherein a sample of seed of said cultivar has been deposited under ATCC Accession No. PTA-124240.
US Pat. No. 10,137,112

METHODS FOR TREATING HYPERURICEMIA IN PATIENTS WITH GOUT USING HALOFENATE OR HALOFENIC ACID AND A SECOND URATE-LOWERING AGENT

CymaBay Therapeutics, Inc...

1. A method for reducing the number, duration, frequency, or intensity of gout flares in a subject, comprising concomitant administration to the subject of a therapeutically effective amount of:(a) a first urate-lowering agent that is (?)-halofenate, or (?)-halofenic acid or a pharmaceutically acceptable salt thereof, substantially free from its (+)-enantiomer; and
(b) a second urate-lowering agent that is febuxostat.
US Pat. No. 10,136,601

WHEAT CULTIVAR Y9A12-0004

Monsanto Technology LLC, ...

1. A plant of wheat cultivar Y9A12-0004, wherein a sample of seed of said cultivar has been deposited under ATCC Accession No. PTA-124243.
US Pat. No. 10,137,113

5-HT4 RECEPTOR AGONIST AS A PROKINETIC AGENT

RaQualia Pharma Inc., Ai...

1. A method for the treatment of gastrointestinal diseases characterized by decreased upper gastrointestinal (GI) motility and decreased lower GI motility by stimulating the upper and lower GI motilities, which comprises administering to an animal subject including a mammalian subject in need thereof 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid or a pharmaceutically acceptable salt thereof in an amount which is therapeutically effective to stimulate both upper and lower GI motilities at the same dose of about 0.005 to 50 mg per day/60 kg weight of the subject being treated.
US Pat. No. 10,137,625

BIAXIALLY ORIENTED BIO-BASED POLYESTER FILMS AND LAMINATES

TORAY PLASTICS (AMERICA),...

1. A laminate film comprising:a biaxially oriented bio-based polyester resin-containing layer comprising crystalline polymer and having a radiocarbon content of at least 21.5 pMC,
wherein both surfaces of the bio-based polyester resin-containing layer comprise particulate antiblock or slip additives, and
a metal layer on a discharge-treated surface of the laminate bio-based polyester film,
wherein the film has an oxygen transmission rate of 5-50 cc/m2/day at 23 degrees Celsius and 0% RH, and a water vapor transmission rate of 0.03-0.70 g/m2/day at 38 degrees Celsius and 90% RH.
US Pat. No. 10,136,602

SOYBEAN VARIETY 01068087

Monsanto Technology LLC, ...

1. A plant of soybean variety 01068087, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124836.
US Pat. No. 10,137,114

RIFAXIMIN READY-TO-USE SUSPENSION

LUPIN LIMITED, (IN)

1. A process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin wherein the said process comprises the steps of dispersing rifaximin in a suspension base comprising one or more pharmaceutically acceptable additive(s) and further milling the suspension to obtain a homogenously dispersed rifaximin suspension; wherein the suspension has a viscosity from about 20Cps to about 200 Cps and is stable for 90 days under conditions of 40° C. and 75% relative humidity.
US Pat. No. 10,138,395

ABRASIVE PARTICLE-DISPERSION LAYER COMPOSITE AND POLISHING SLURRY COMPOSITION INCLUDING THE SAME

KCTECH CO., LTD., Anseon...

1. An abrasive particle-dispersion layer composite comprising:abrasive particles;
a first dispersant being at least one anionic compound selected from the group consisting of a copolymer with a functional group of a resonance structure, a carboxyl group-containing polymer and a carboxyl group-containing organic acid;
a second dispersant being at least one cationic compound selected from the group consisting of an amino acid, an organic acid, polyalkylene glycol and a high-molecular polysaccharide coupled to a glucosamine compound; and
a third dispersant being a cationic polymer comprising at least two ionized cations in a molecular formula.
US Pat. No. 10,139,419

METHODS FOR DETECTING A? OLIGOMERS

SYSTEM OF SYSTEMS ANALYTI...

1. A method of determining the amyloid beta (A?) oligomer load of a subject by detecting A? oligomer associated with cells present in a biological sample obtained from the subject, comprising:preparing a first test sample comprising a biological sample from the subject that comprises cells and a peptide probe,
wherein the peptide probe consists of from 10 to 34 amino acid residues comprising an amino acid sequence that is at least 70% identical to any one of SEQ ID NOs:1-56 and 62-65, wherein the peptide probe preferentially binds to A? oligomers and is labeled with a detectable fluorescent label, wherein the peptide probe forms a first labeled complex with the A? oligomers on A? oligomer-associated cells in the biological sample;
detecting a generated signal of the first labeled complex in the first test sample using flow cytometry;
preparing a second test sample comprising a biological sample from the subject that comprises cells, synthetic A? oligomer, and the peptide probe, wherein the peptide probe forms second labeled complexes with A? oligomers on A? oligomer-associated cells in the biological sample and with synthetic A? oligomer;
detecting a generated signal of the second labeled complexes in the second test sample using flow cytometry;
wherein a difference between the signal of the first labeled complex in the first test sample and the signal of the second labeled complexes in the second test sample is inversely correlated with the A? oligomer load of the subject.
US Pat. No. 10,141,216

ROOM TEMPERATURE DEBONDABLE AND THERMALLY CURABLE COMPOSITIONS

PROMERUS, LLC, Brecksvil...

1. A method of fabricating a semiconductor device comprising:forming a first polymer layer over a surface of a first substrate having structures thereon where said polymer layer comprises a thermally stable and crosslinkable polymer and a surface energy modifier featuring both hydrophilic and hydrophobic properties;
forming a second polymer layer over a surface of a second substrate where second polymer comprises said thermally stable and cross-linkable polymer and a crosslinking agent;
wherein said thermally stable and crosslinkable polymer is selected from the group consisting of:
styrene-diene copolymers; and
ethylene, propylene, diene monomer (EPDM) polymers;
bonding thermally said surface of first substrate with said surface of second substrate at a first temperature, said first temperature being lower than a crosslinking temperature of said crosslinking agent;
subjecting said bonded substrates to a second temperature so as to allow crosslinking and direct bonding of said first polymer layer on first substrate with said second polymer layer on said second substrate, said second temperature being higher than said first temperature; and
wherein said first polymer layer is a release layer of thickness larger than the height of said structures on first substrate and is about 15 to 20 microns thick and said second polymer layer is an adhesive layer, wherein combined thickness of said release layer and said adhesive layer is about 50 microns; and
debonding said first substrate from said second substrate at room temperature by applying a mechanical force.
US Pat. No. 10,136,603

SOYBEAN VARIETY 01067535

Monsanto Technology LLC, ...

1. A plant of soybean variety 01067535, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124908.
US Pat. No. 10,137,115

THERAPEUTIC INHIBITOR FOR EBV-ASSOCIATED TUMOR WITH TAILOR RESPONSIVE OPTICAL IMAGING

Hong Kong Baptist Univers...

1. A nucleus-permeable small-molecule inhibitor comprising 4-(4-(Diethylamino)styryl)-N-carboxymethylpyridinium chloride coupled to an amino acid sequence comprising CAhxYFMVFGGRrRK (SEQ ID NO. 3) through an amide bond Ahx is 6-aminohexanoic acid.
US Pat. No. 10,138,396

POLISHING COMPOSITION

FUJIMI INCORPORATED, (JP...

1. A polishing composition used for polishing an object to be polished containing oxygen atoms and silicon atoms,the polishing composition comprising: abrasive grains A having an average primary particle size of 3 nm or more and 8 nm or less; abrasive grains B having an average primary particle size of more than 8 nm; and a dispersing medium, wherein
a content of the abrasive grains B in the polishing composition is larger than a content of the abrasive grains A in the polishing composition,
average silanol group density of the abrasive grains A and the abrasive grains B is 2.0 nm-2 or less, and
an aspect ratio of the abrasive grains B is more than 1.3 and 2.0 or less.
US Pat. No. 10,139,420

METHODS FOR TREATING VASO-OCCLUSIVE CRISIS USING NON-MODIFIED ANNEXIN V

ISNERM (Institut National...

1. A method for preventing or treating a vaso-occlusive crisis in a patient suffering from sickle cell disease comprising the step of administering to said patient a non-modified annexin V.
US Pat. No. 10,136,604

MAIZE INBRED PH42YN

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH42YN, representative seed of the variety having been deposited under ATCC accession number PTA-124769.
US Pat. No. 10,136,605

MAIZE INBRED PH41JG

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH41JG, representative seed of the variety having been deposited under ATCC accession number PTA-124811.
US Pat. No. 10,138,398

LOW APPLICATION TEMPERATURE HOT MELT ADHESIVE

1. A low application temperature hot melt adhesive comprising:(a) at least about 5 wt % to about 25 wt % of an olefin block copolymer, wherein having an average Melt Index range of greater than 5 and less than about 35 g/10 minutes at 190° C.;
(b) from about 40 to about 70 wt % of a tackifier;
(c) from about 0.5 to about 5 wt % a wax;
(d) from about 1 to about 30 wt % of a plasticizer diluent; and
(e) from 0 to about 5 wt % of an optional component;
wherein the adhesive has a viscosity of below about 11,000 centipoises at 120° C., a yield stress (12 in/min extensional rate) range of from about 7 to about 50 psi at 25° C., and a cross-over temperature (when G?=G?) greater than about 70° C.; and
wherein the sum of the total wt % of the adhesive equals to 100.
US Pat. No. 10,139,422

THROUGHPUT OPTIMIZING REAGENT DISTRIBUTION

Siemens Healthcare Diagno...

1. A method for distributing sample tests in an IVD environment comprising:identifying a plurality of expected tests to be performed by a plurality of analyzer modules on a plurality of patient fluid samples stored in sample vessels;
determining information about the capabilities of the plurality of analyzer modules;
receiving, at a processor, incompatibility data identifying which of the plurality of expected tests are incompatible, where two tests within the plurality of expected tests are identified as incompatible when a pipette that interacts with the plurality of patient fluid samples would need to spend at least one cycle doing one of sitting idle due to a resource allocation conflict between the two tests and performing a washing operation due to a chemistry conflict between the two tests;
calculating, by the processor, using the incompatibility data, a distribution of the plurality of expected tests amongst the plurality of analyzer modules that minimizes both resource allocation conflicts and chemistry conflicts;
allocating reagents to each of the plurality of analyzer modules by selectively distributing a plurality of reagents to each of the plurality of analyzer modules in accordance with the calculated distribution of expected tests;
scheduling the plurality of patient fluid samples to undergo tests at the plurality of analyzer modules in accordance with the calculated distribution of expected tests; and
moving the sample vessels via an automation system such that at least a subset of the plurality of patient fluid samples each undergo tests by at least two of the plurality of analyzer modules to complete a plurality of test panels in accordance with the scheduling step,
wherein the step of calculating a distribution of the plurality of expected tests comprises using a search algorithm to identify at least one solution that exceeds a compatibility threshold.
US Pat. No. 10,136,606

MAIZE INBRED PH471G

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH471G, representative seed of the variety having been deposited under ATCC accession number PTA-124817.
US Pat. No. 10,136,607

MAIZE INBRED PH432T

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH432T, representative seed of the variety having been deposited under ATCC accession number PTA-124802.
US Pat. No. 10,138,400

HOT MELT ADHESIVE

1. A hot melt adhesive agent comprising:(A) 3 to 60 parts by weight of a thermoplastic block copolymer consisting only of a radial styrene-conjugated diene block copolymer having (i) a styrene content of 35 to 45% by weight and a diblock content of 50 to 90% by weight (ii) a viscosity less than 250 mPa·s at 25° C. and 25% by weight in toluene solution;
(B) about 60 to about 85 parts by weight of a tackifier; and
(C) about 15 to about 20 parts by weight of an oil;
wherein the conjugated diene compound is selected from the group consisting of 1,3-butadiene, 2,3-dimethyl-1,3-butadiene, 1,3-pentadiene, 1,3-hexadiene and combinations thereof.
US Pat. No. 10,136,608

TOBACCO HAVING REDUCED AMOUNTS OF AMINO ACIDS AND METHODS FOR PRODUCING SUCH LINES

Reynolds Technologies, In...

1. A method for producing a modified tobacco plant comprising generating a tobacco plant comprising a reduced level of asparagine, such that the tobacco plant or a portion thereof generates a reduced level of acrylonitrile upon heating or burning as compared to an unmodified parent tobacco plant or a portion thereof, wherein the producing comprises the steps of exposing a tobacco seed from the unmodified tobacco plant to a mutagen and then growing a seedling generated from the seed in the presence of leucine as a selection agent.
US Pat. No. 10,136,609

BRASSICA RAPA VAR NIPPOSINICA NAMED ORIGAMI

SHAMROCK SEED COMPANY, IN...

1. A seed of Brassica rapa var. nipposinica designated ORIGAMI, wherein a representative sample of seed of said Brassica rapa var. nipposinica has been deposited under NCIMB No. 43075.
US Pat. No. 10,137,121

METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS

Kura Oncology, Inc., San...

1. A method of treating an angioimmunoblastic T-cell lymphoma (AITL) in a subject, comprising administering a therapeutically effective amount of tipifarnib to the subject.
US Pat. No. 10,138,402

ANTISTATIC AGENT, ANTISTATIC AGENT COMPOSITION, ANTISTATIC RESIN COMPOSITION, AND MOLDED BODY

ADEKA CORPORATION, Tokyo...

1. An antistatic agent comprising a polymer compound (E) having a structure in which a diol, an aliphatic dicarboxylic acid, an aromatic dicarboxylic acid, a compound (B) which comprises at least one group represented by the following Formula (1) and has hydroxyl groups at both ends, and an epoxy compound (D) having two or more epoxy groups are bound via ester bonds:—CH2—CH2—O—  (1).
US Pat. No. 10,136,610

GARDEN BEAN NAMED HMX5106

HM.CLAUSE, INC., Davis, ...

1. A seed of bean cultivar designated HMX5106, wherein a representative sample of seed of said cultivar has been deposited under NCIMB No. 43073.
US Pat. No. 10,137,123

METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY

University of Hawaii, Ho...

1. A method of treating heart failure of any cause in a mammalian subject comprising administering to the subject an effective amount of an ion channel TRPV1 inhibitor, with the proviso that if the heart failure is caused by acute myocardial ischemia, the administering of the ion channel TRPV1 inhibitor occurs after the therapeutic window for protection from acute myocardial ischemia.
US Pat. No. 10,138,405

FIBER SUSPENDING AGENT FOR LOST-CIRCULATION MATERIALS

Halliburton Energy Servic...

1. A treatment fluid comprising:a base fluid;
a lost-circulation material, wherein the lost-circulation material inhibits or prevents some or all of the treatment fluid from penetrating into a subterranean formation from a wellbore, wherein the wellbore penetrates the subterranean formation; and
a suspending agent, wherein the suspending agent consists of a plurality of fibers, wherein the fibers have a length to diameter aspect ratio of about 100:1 to about 5000:1, wherein the fibers have a distribution such that at least 90% of the fibers have a length in the range of about 5 to about 25 millimeters; and wherein the suspending agent is in at least a sufficient concentration to provide a lost-circulation material distribution of at least 30% for a test treatment fluid consisting essentially of the base fluid, the lost-circulation material, and the suspending agent at a temperature of a lost-circulation zone of the subterranean formation and after performing static aging for at least 1 hour.
US Pat. No. 10,138,406

LUBRICATION FOR DRILLING FLUID

1. A modified drilling fluid comprising:a water-based drilling fluid in a range of from 95 vol. % to 99 vol. %; and
a drilling fluid lubricant in a range of from 0.1 vol. % to 5 vol. % of the fluid,where the drilling fluid lubricant comprises:a crude tall oil product that is selected from the group consisting of: crude tall oil; distilled tall oil; acid tall oil; fractionated tall oil; and combinations thereof, and;
an at least partially transesterified derivative of ricinoleic acid product that is comprised of at least partially transesterified derivatives of ricinoleic acid, wherein the volume ratio of the derivative of ricinoleic acid to the crude tall oil product is between about 1:1 to about 1:3, and wherein the derivative of ricinoleic acid is present at about at least 10 vol. % of the drilling fluid lubricant.
US Pat. No. 10,137,126

METHOD OF PREPARING VERY SLIGHTLY SOLUBLE DRUG WITH SOLID DOSAGE FORM

YUNG SHIN PHARM. IND. CO....

1. A method of preparing a very slightly water soluble drug with a solid dosage form including the following steps:(a) Adding a very slightly soluble drug into an organic solvent and a polysorbate to form a first solution;
(b) Adding the first solution into a second solution and at least one pharmaceutically acceptable excipient to obtain a mixture, wherein the second solution comprises water or sodium lauryl sulfate (SLS), and a volume ratio of the first solution and the second solution is between 8:1 and 1:1; and
(c) Drying and compressing the mixture in step (b) to form a very slightly soluble drug with a solid dosage form.
US Pat. No. 10,138,408

AMIDE BRANCHED AROMATIC CELLING AGENTS

Synoil Fluids Holdings In...

1. A downhole fluid comprising a base fluid, a gelling agent with an aromatic core of more than one aromatic ring, the gelling agent having four or more amide branches distributed about the aromatic core, each of the four or more amide branches (i) being connected to the aromatic core via a carbon-nitrogen bond or a carbon-carbon bond, (ii) having a first side chain that is a hydrogen and (iii) having a second side chain with one or more organic groups.
US Pat. No. 10,137,128

METHODS OF IMPROVING MYOCARDIAL PERFORMANCE IN FONTAN PATIENTS USING UDENAFIL COMPOSITIONS

Mezzion Pharma Co., Ltd.,...

1. A method of treating an adolescent with single ventricle heart disease for improving the adolescent's exercise capacity or for increasing the likelihood of improving the adolescent's exercise capacity, whose exercise capacity is adversely affected due to a decline in the adolescent's heart function after Fontan palliation, wherein the adolescent is in need of treatment to improve the adolescent's exercise capacity, or to increase the likelihood of improving the adolescent's exercise capacity as determined by maximum oxygen uptake at maximum exercise output (VO2 measurement), said method comprising:orally administering to the adolescent in accordance with a treatment regimen an oral dosage form comprising an effective dose of udenafil, or a pharmaceutically acceptable salt thereof, to improve the adolescent's VO2 measurement or to increase the likelihood of improving the adolescent's VO2 measurement for improving the adolescent's exercise capacity or for increasing the likelihood of improving the adolescent's exercise capacity,
wherein the adolescent is a human,
wherein the adolescent has undergone Fontan surgery,
wherein the human adolescent is between about 12 years old and under about 18 years old,
wherein the effective dose of udenafil, or a pharmaceutically acceptable salt thereof, is about 87.5 mg, and
wherein the treatment regimen comprises orally administering the oral dosage form to the human adolescent twice daily.
US Pat. No. 10,137,129

PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR DIFFUSE LARGE B-CELL LYMPHOMA

ONO PHARMACEUTICAL CO., L...

1. A method of treating B-cell non-Hodgkin's lymphoma comprising: administering to a human in need thereof a pharmaceutically effective amount of 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one or a salt thereof and at least one additional anticancer agent; wherein the at least one additional anticancer agent comprises a Bcl-2 inhibitor selected from navitoclax, ABT-737, and ABT-199.
US Pat. No. 10,138,154

METHOD FOR PRODUCING A DENTAL PROSTHESIS

DENTSPLY SIRONA Inc., Yo...

and at least one additive between 0.1 and 5 wt-%, the additive being selected from the group consisting of BaO, CaO, MgO, MnO, Er2O3, Gd2O3, Na2O, Pr2O3, Pr6O11, Sm2O3, TiO2, V2O5, and Y2O3,
(b) producing spherical or lens-shaped glass particles solidified from the melt;
(c) portioning the glass particles and filling them into a crucible;
(d) melting the glass particles in the crucible and setting a viscosity v, wherein 4 dPa·s?v?80 dPa·s;
(e) casting the thus produced melt into a negative mold which is enclosed by an embedding compound and corresponds to the dental prosthesis to be produced;
(f) solidifying the melt in the negative mold;
(g) crystallizing lithium metasilicate as main crystalline phase from the solidified melt by employing a first heat treatment at a temperature between 600° C. and 760° C. over a time between 20 min and 120 min, and
(e) comprising the step of crystallizing lithium disilicate as main crystalline phase in a second heat treatment at a temperature between 760° C. and 860° C. over a time between 5 min and 60 min;
wherein the first and second heat treatment of the solidified melt takes place either in the negative mold or after removal from the negative mold.
US Pat. No. 10,138,412

HYDRAULIC FRACTURING COMPOSITIONS INCLUDING NOVEL VISCOSIFYING SYSTEMS AND METHODS FOR MAKING AND USING SAME

KEANE GROUP HOLDINGS, LLC...

1. A method for fracturing a formation comprising:pumping a fracturing fluid composition into a formation at a pressure sufficient and for a time sufficient to fracture the formation,
wherein the fracturing fluid composition comprises:
a base fluid,
a polymer system including:
a major portion of one partially hydrolyzed polyacrylamide polymer or a plurality of partially hydrolyzed polyacrylamide polymers, and
a minor portion of one natural hydratable polymer or a plurality natural hydratable polymers, and
an effective amount of a viscosifying system including one guanidine salt or a plurality of guanidine salts,
wherein the major portion is an amount greater than or equal to 50 wt. % and the minor portion is an amount less than or equal to 50 wt. %, and
wherein the effective amount is sufficient to increase the viscosity of the synthetic polymer system by 20% or more compared to fracturing fluids including only the polymer system.
US Pat. No. 10,137,132

PARENTERAL FORMULATIONS OF DOPAMINE AGONISTS

VeroScience, LLC, Tivert...

1. A stable parenteral dosage form comprising at least one dopamine agonist selected from the group consisting of 2-bromo-a-ergocriptine (bromocriptine), terguride, dihydroergotoxine (hydergine), erfotoxine, 6-me-thyl 8-carbobenzyloxy-aminoethyl-10-a-ergoline, 8-acy-laminoergoline, 6-methyl-8-a-(N-acyl)amino-9-ergoline, lisuride, dihydro-alpha-ergocriptine, dihydro-alpha-ergotox-ine, 6-methyl-8-a-(N-phenyl-acety)amino-9-ergoline, ergo-cornine, 9,10-dihydroergocornine, any D-2-halo-6-alkyl-8-substituted ergoline, and D-2-bromo-6-methyl-8-cyanomethylergoline, dopamine, apomorphine, SKF38393, dihydrexidine, SKF 75670, SKF 82957, SKF 81297, SKF 82958, SKF 82598, A77636, A68930, and SKF 82526 (fenoldopam), in particulate form and at least one pharmaceutically acceptable excipient selected from the group consisting of a bioadhesion enhancer, a permeation enhancer and a stabilizer, said particulate dopamine agonist being present in a first portion containing particles of between 0.1 and 5.0 ?m and a second portion containing particles of between 10 and 200 ?m,said dopamine agonist and said at least one pharmaceutically acceptable excipient being present in amounts that provide the dosage form with a pharmacokinetic profile comprising
a) a Tmax at about 1 to about 90 minutes after administration of the parenteral dosage form;
b) a plasma drug concentration of at least 50% Cmax for a duration of about 90 to about 360 minutes after Tmax when said dosage form is administered parenterally.
US Pat. No. 10,136,621

METHOD OF PRODUCING INFERTILE FISH AND EGG-PRODUCING AQUATIC ANIMALS AND OF DELIVERING COMPOUNDS INTO EGGS AND EMBRYOS

UNIVERSITY OF MARYLAND BA...

1. A composition for treatment of fish eggs to render fish produced therefrom reproductively sterile, said composition comprising an anti-sense Morpholino oligomer conjugated to an octaguanidine dendrimer molecular transporter, wherein said anti-sense Morpholino oligomer suppresses the translation of dead end gene in said fish.
US Pat. No. 10,137,135

FORMULATIONS AND METHODS FOR PROVIDING PROGESTIN-ONLY CONTRACEPTION WHILE MINIMIZING ADVERSE SIDE EFFECTS ASSOCIATED THEREWITH

Allergan Sales, LLC, Irv...

1. A method of providing progestin-only contraception to a woman while minimizing adverse side effects associated with the progestin-only contraception, comprising the steps of:1) applying a transdermal patch to the outer skin surface of a woman and allowing the patch to remain applied to the outer skin surface of the woman for at least seven days; and
2) removing the transdermal patch from the outer skin surface after about seven days wherein the transdermal patch comprises norethindrone and/or norethindrone acetate as the only active hormonal agents in an amount of from about 1% w/w to about 15% w/w of the transdermal formulation and a permeation enhancer comprising isopropyl myristate and lauryl alcohol in an amount from about 3% w/w to about 15% w/w of the transdermal patch; and
the norethindrone and/or norethindrone acetate are administered from the transdermal patch at a rate and amount that provides a minimum norethindrone serum level of at least 300 pg/ml from about 24 hours to about 168 hours following application of the patch to the outer skin surface and a maximum norethindrone serum level of less than 1200 pg/ml about 24 to 96 hours following application of the patch to the outer skin surface.
US Pat. No. 10,138,416

CONTROL OF PARTICULATE ENTRAINMENT BY FLUIDS

Trican Well Service, Ltd,...

1. A method of hydraulic fracturing of a formation, comprising:a) making a hydraulic fracturing fluid composition by:
i) contacting sand proppants having a surface with a medium containing a chemical compound to render the surface of the proppants hydrophobic, wherein the chemical compound is an organosilane;
ii) separating the proppants from the medium; and
iii) mixing the proppants with water and an oil to form a mixture; and
b) pumping the mixture into the formation.
US Pat. No. 10,137,136

METHODS FOR INHIBITING MUSCLE ATROPHY

UNIVERSITY OF IOWA RESEAR...

1. A method for enhancing muscle formation, increasing muscle mass, or reducing muscle atrophy in an animal identified or having been identified to be in need of enhanced muscle formation, increased muscle mass, or reduced muscle atrophy, the method comprising administering to the animal an effective amount of ursolic acid or a salt, solvate, or polymorph thereof, thereby enhancing muscle formation, increasing muscle mass, or reducing muscle atrophy in the animal, wherein said animal:(a) is a primate that has not been diagnosed with a need for treatment of diabetes; or
(b) is selected from the group consisting of a domesticated fish, domesticated crustacean, domesticated mollusk, poultry, rabbit, dog, cat, guinea pig, and livestock.
US Pat. No. 10,138,417

PROPPANT COMPRISING AN OIL WELL TREATMENT AGENT COATING

Dow Global Technologies L...

1. A coated proppant for treating oil comprisingi) a particle, and
ii) a coating comprising a treatment agent comprising
a an ethylene-vinyl acetate copolymer in an amount of from 80 to 99 weight percent, and
b a dispersing agent in an amount of from 1 to 20 weight percent, wherein weight percents are based on the total weight of the coating, and
iii) a cross-linked polyurethane polymer,
wherein the coating will dissolve in oil such that the treatment agent can treat the oil.
US Pat. No. 10,138,163

PROCESS FOR MANUFACTURING A MILK OF SLAKED LIME OF GREAT FINENESS AND MILK OF GREAT FINENESS THEREBY OBTAINED

S. A. Lhoist Recherche et...

1. Process for manufacturing a milk of lime of great fineness wherein said milk of lime comprises slaked lime particles in suspension into an aqueous phase, the slaked lime particles having a d50 greater than or equal to 2 ?m and lower than or equal to 6 ?m, measured by means of a laser granulometer in methanol, comprising at least the steps of:(a) adding water to quicklime instead of addition of quicklime to water to obtain a paste of lime and
(b) forming a milk of slaked lime of great fineness with said paste of lime.
US Pat. No. 10,137,140

THERAPEUTIC COMPOSITION

Dermarc LLC, Wayne, PA (...

1. A pharmaceutical topical gel formulation comprising:about 0.125% furosemide;
about 0.125% digoxin;
alkylene glycol in the range of about 20-60% w/w;
ethanol in the range of about 20-60% w/w;
at least one thickener in the range of about 0.5% to 5% w/w;
a buffer which maintains the formulation pH at about pH 3 to about pH 8, wherein the buffer is citric acid and sodium citrate present in the formulation at 7.5 mmol/l to 15 mmol/l; and
optionally, polyalkylene glycol in the range of about 0-20% w/w;
q.s. with water,
wherein the concentrations are based on the total weight of the formulation, further wherein the topical gel formulation is anti-viral.
US Pat. No. 10,137,141

TREATMENT REGIMEN TIACUMICIN COMPOUND

Astellas Pharma Europe Lt...

1. A method of treating a Clostridium difficile infection (CDI) or Clostridium difficile associated diarrhea or disease (CDAD) in a patient according to a dosage regimen selected from the group consisting of:i. administering orally to the patient 200 mg of a tiacumicin compound, a stereoisomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof BID for 5 days followed by 5 days of rest and then 200 mg once daily for a further 10 days and
ii. administering orally to the patient 200 mg of a tiacumicin compound, a stereoisomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof orally BID for 5 days followed by a single 200 mg every other day for 20 days.
US Pat. No. 10,138,422

PREPARATION PROCESS OF A FLAME RETARDANT COMPOSITION MADE FROM BROMINATED BISMUTH AND/OR ANTIMONY COMPOUNDS COMPLEXED WITH MELAMINE AND COMPOSITION OBTAINED THEREBY

Sichim Alfa S.r.l., Rave...

1. Flame retardant composition, characterized in that it is composed of: a complex having a formula ML(MeBr3), where ML indicates melamine and Me is bismuth or antimony; melamine bromohydrate; at least one among the compounds chosen from the group consisting of melamine, melamine phosphate, melamine polyphosphate, ammonium phosphate, ammonium polyphosphate, graphite, silica, lignin, triphenyl-phosphate, coke and compounds containing triazine rings condensed or linked by —NH groups; and optional additives; wherein the composition is composed of:20-65% in weight of said complex having the formula ML (MeBr3);
20-65% in weight of melamine bromohydrate;
10-40% in weight of at least one among the compounds chosen from the group consisting of melamine, melamine phosphate, melamine polyphosphate, ammonium phosphate, ammonium polyphosphate, graphite, silica, lignin, triphenyl-phosphate, coke and compounds containing triazine rings condensed or linked by —NH groups;
0-3% of additives.
US Pat. No. 10,137,142

TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT

Dow Pharmaceutical Scienc...

1. An aqueous formulation for topical application to the skin comprising about 3.75% w/w benzoyl peroxide, about 5.0% w/w propylene glycol, about 1.2% w/w clindamycin phosphate, about 1.75% w/w carboxyvinyl polymer gelling agent and about 87.8% w/w water.
US Pat. No. 10,137,143

PREVENTING TUMOR DEVELOPMENT AND METASTASIS

The Administrators of the...

1. A pharmaceutical composition for the treatment of a tumor having increased expression of TRAF3IP2, wherein said composition comprises at least one silencing sequence for TRAF3IP2 in a pharmaceutically acceptable nucleic acid carrier in an amount effective for the therapeutic treatment of a tumor, wherein said silencing sequence reduces the expression of the TRAF3IP2 gene by at least 65% as comparing to without the silencing sequence for TRAF3IP2, and wherein said silencing sequence is a modified portion of sense strand of SEQ ID NO. 7, wherein the portion is about 18-30 nt in length.
US Pat. No. 10,138,167

THERMAL SPRAY MATERIAL, THERMAL SPRAY COATING AND THERMAL SPRAY COATED ARTICLE

TOKYO ELECTRON LIMITED, ...

1. A thermal sprayed article comprising:a substrate; and
a thermal spray coating deposited on a surface of the substrate by thermal spraying of the thermal spray material, the thermal spray material comprising a yttrium oxyfluoride comprising a yttrium (Y), oxygen (O) and a fluorine (F) as its elemental constituents, the yttrium oxyfluoride having a molar ratio (F/Y) of the fluorine to the yttrium of 1.1 or greater,
wherein the thermal spray coating comprises a Y6O5F8 phase.
US Pat. No. 10,137,144

METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLS

American Gene Technologie...


US Pat. No. 10,137,145

MENINGOCOCCAL VACCINE BASED ON LIPOOLIGOSACCHARIDE (LOS) ORIGINATING FROM MODIFIED NEISSERIA MENINGITIDIS STRAINS OF IMMUNOTYPE L6

Sanofi Pasteur SA, Lyons...

1. A process for preparing a lipooligosaccharide (LOS) of Neisseria meningitidis, the process comprising(a) culturing a modified a modified N. meningitidis strain exhibiting a lipooligosaccharide (LOS) comprising a lipid A, an inner core, and an L8 type alpha chain in which the heptose II residue of the inner core bears in position 0-3 and in position 0-6 or position 0-7 a phosphoethanolamine (PEA) substituent, wherein the modified N. meningitidis strain is made by a process comprising modifying an N. meningitidis strain of immunotype L8 so that it expresses an N. meningitidis lpt6 gene; and
(b) harvesting the LOS from the culture of (a);wherein the LOS comprises a lipid A, an inner core, and an alpha chain of L8 immunotype, and wherein the heptose II residue of the inner core bears in position 0-3 and in position 0-6 or position 0-7 a phosphoethanolamine (PEA) substituent.
US Pat. No. 10,137,146

OXYGEN-ENABLED COMPOSITION

BAYLOR UNIVERSITY, Waco,...

1. A composition, comprising:a poly-oxygenated aluminum hydroxide comprising a clathrate containing oxygen gas molecules that is chlorine-free and soluble in a fluid.
US Pat. No. 10,138,171

METHOD FOR ALTERING PHOTOSYNTHETIC GROWTH

1. A method for reducing or enhancing photosynthetic activity of a photosynthetic organism, the method consisting essentially of providing a form of pigmented matter, fertilizer, and optionally an adhesive material to the photosynthetic organism, wherein the pigmented matter is sprayed onto the leaves of the photosynthetic organism, and the pigmented matter contains chlorophyll.
US Pat. No. 10,138,172

METHODS, SYSTEMS AND WORKPIECES USING MECHANOSYNTHESIS

CBN Nano Technologies, In...

1. A system for building a workpiece comprising:a specification for a three-dimensional, atomically-precise workpiece;
a build sequence for building said workpiece with a desired level of reliability;
a means of providing feedstock;
a means to position said feedstock; and
a means to cause mechanosynthetic reactions with said feedstock, to create said workpiece,
wherein at least some of said mechanosynthetic reactions have a calculated temperature-dependent reliability of at least about 93.8% at 77K.
US Pat. No. 10,138,429

METHOD FOR STARTING UP A FISCHER TROPSCH PROCESS

SHELL OIL COMPANY, Houst...

1. A Fischer-Tropsch catalyst that comprises:titania
between 5 to 35 weight percent cobalt, calculated on the total weight of the catalyst
in the range of between to 0.1 to 15 weight percent promoter, whereby the promoter comprises manganese, rhenium, Group 8-10 noble metals, or mixtures thereof;
and more than 0.7 and less than 4 weight percent of the element chlorine, calculated on the total weight of the catalyst.
US Pat. No. 10,136,637

PESTICIDE NANO-SUSPENSION

AGFORM LIMITED, Southham...

1. A composition comprising an aqueous dispersion of particles, wherein the particles comprise a surface active agent and one or more active agents selected from herbicides, insecticides or fungicides, the mean particle diameter is 500 nanometers or less, the surface active agent is a polyetheralkanolamine comb polymer, and wherein the composition comprises at least 25% by weight of active agent.
US Pat. No. 10,137,149

PARTICLES FOR THE TREATMENT OF CANCER IN COMBINATION WITH RADIOTHERAPY

Oxford University Innovat...

1. A method of treating cancer in a subject comprising:administering a particle to a locus or site of the cancer or to tumour tissue in the subject, which particle comprises a metal oxide, which metal oxide is titanium dioxide doped with from 0.1 to 25 mol % of at least one rare earth element, wherein the titanium dioxide is a host lattice and the at least one rare earth element is present as a dopant within said host lattice; and
applying X-ray radiation suitable for radiotherapy to the locus or site of the cancer or tumour tissue and thereby exciting the metal oxide in the particle at the locus or site of the cancer or tumour tissue and generating reactive oxygen species at the locus or site of the cancer or tumour tissue.
US Pat. No. 10,138,173

ZONE REFINING METHOD FOR NUTRACEUTICALS

White Flower Associates, ...

1. A method for purifying an organic compound, comprising the following steps:(i) providing a crystalline sample of organic compound having a first impurity level,
(ii) adding a catalyst to the sample,
(iii) heating a portion of the sample to a temperature at or above melting point of the organic compound so as to create a molten zone of the sample,
(iv) moving application of heat down the length of the sample, such that the molten zone is moved along the length of the sample,
(v) collecting molten material at an end of the sample,
(vi) optionally grinding the sample back to a powder,
(vii) repeating steps (i)-(iv) at least two more times, and
(viii) obtaining a purified sample having a second impurity level, which is lower than the first impurity level,
wherein the organic compound is a nutraceutical selected from the group consisting of vinpocetine, huperzine, astrazaloside IV, HEPPS buffer, curcumin, piperine, uridine, capsaicin and kinetin.
US Pat. No. 10,138,430

CONVERSION OF LIPIDS INTO OLEFINS

1. A method of conversion of a lipid to an olefin product, comprising the steps of heating a mixture of unsaturated triacylglycerols or alkyl esters of unsaturated fatty acids and a reactant olefin with microwave irradiation, in the presence of a ruthenium complex catalyst in reaction conditions sufficient to convert the mixture into an effluent comprising the olefin product.
US Pat. No. 10,137,150

GRAPHENE AND GRAPHENE-RELATED MATERIALS FOR MANIPULATION OF CELL MEMBRANE POTENTIAL

1. An activating system comprising:at least one biointerface adapted to generate free charge carriers in response to exposure to electromagnetic radiation, the at least one biointerface comprising one or more materials comprising at least one graphene sheet, graphene oxide, reduced graphene oxide, graphite, graphite oxide, or combinations thereof;
at least one source of electromagnetic radiation adapted configured to expose the at least one biointerface to the electromagnetic radiation; and
at least one biological target comprising live cells that contact or are positioned in sufficient proximity to the at least one biointerface such that cell membrane potentials of the live cells are remotely and reversibly manipulated by the free charge carriers generated by exposure of the at least one biointerface to the electromagnetic radiation.
US Pat. No. 10,138,175

PARTICLES INCLUDING ZEOLITE CATALYSTS AND THEIR USE IN OLIGOMERIZATION PROCESSES

ExxonMobil Chemical Paten...

1. A process for the oligomerization of olefins, the process comprising contacting at least one spheroid particle with a feedstock under oligomerization conditions to form at least one oligomer product,wherein the spheroid particle has an average particle size of from 0.1 mm to 5.0 mm and comprises the product of:
(1) at least one zeolite catalyst which comprises TON or MFS framework structure; and
(2) at least one binder which comprises metal oxide and/or clay,
wherein the feedstock comprises one or more of propene, pentenes, hexenes, their isomers, and mixtures thereof.
US Pat. No. 10,136,641

METHODS FOR INCREASING TOLERANCE TO ABIOTIC STRESS IN PLANTS

Crop Microclimate Managem...

1. A method for increasing tolerance to abiotic stress and/or reducing the consequence of abiotic stress in a plant or part thereof growing under field conditions, comprising:contacting said plant or part thereof growing under field conditions with a composition comprising an effective amount of azelaic acid (nonanedioic acid, HOOC—(CH2)7—COOH) and/or a salt thereof, wherein the concentration of azelaic acid in the composition is from about 1×10?9 M to less than 1×10?6 M and the plant or plant part is not sugarbeet, thereby increasing tolerance to abiotic stress and/or reducing the consequence of abiotic stress in said plant and/or plant part thereof growing under field conditions.
US Pat. No. 10,137,153

METHODS FOR TREATING AN INFECTIOUS OR NEOPLASTIC DISEASE

THE TRUSTEES OF COLUMBIA ...

1. A method of treating a subject suffering from an infectious or neoplastic disease with immunotherapy comprising:(a) providing a gel comprising:
(i) collagen and fibrin, which gel is sufficient to support viability of an immune cell and growth of a cell from an infectious or neoplastic disease obtained from the subject; and
ii an immune cell and a cell from an infectious or neoplastic disease obtained from the subject disposed within the gel;
(b) incubating the gel under conditions that support viability of the immune cell and growth of the cell from the infectious or neoplastic disease obtained from the subject for a period of time sufficient to determine whether the immune cell has an effect on the cell from the infectious or neoplastic disease obtained from the subject;
(c) determining the number of viable cells from the infectious or neoplastic disease, if any, that are present after step (b), wherein the determining step comprises carrying out a clonogenic assay to determine how many, if any, infectious or neoplastic disease cells are present;
(d) determining a critical concentration of immune cells required to treat or eradicate the infectious or neoplastic disease in the subject; and
(e)administering to the subject the critical concentration of immune cells determined in step (d).
US Pat. No. 10,136,642

COMPOSITION OF PERACETIC ACID AND AT LEAST ONE ORGANIC FUNGICIDE FOR THE CONTROL AND/OR THE TREATMENT OF DISEASES ASSOCIATED WITH THE PRESENCE OF PATHOGENS, AND METHOD, USE AND KIT INVOLVING SAID COMPOSITION

AGRI-NEO, INC., Toronto,...

1. A composition comprising water soluble ingredients comprising:(i) peracetic acid; and
(ii) at least one organic fungicide,wherein the at least one organic fungicide comprises a fungicide having a mode of action consisting of:I) Respiration and belonging to one of the following sub-groups:inhibition of complex II: succinate-dehydrogenase which are Succinate DeHydrogenase Inhibitors (SDHI);
inhibition of complex I NADH Oxido-reductase which are pyrimidinamines pyrazole-MET1;
inhibition of complex III cytochrome bc1 (ubiquinone reductase) at Qi site which are Quinone Inside Inhibitors Qil fungicides;
inhibition of complex III cytochrome bc1 (ubiquinone reductase) at Qx which are Quinone x Inhibitor Qxl-fungicide;
inhibitors of oxidative phosphorylation ATP synthase which are organo tins;
ATP production (prop.) which are thiophene carboxamides;
uncoupler of oxidative phosphorylation;
or
inhibition of complex III cytochrome bc1 (ubiquinol oxidase) at Qo site (cyt b gene) which are Quinone Outside Inhibitors Qol fungicides selected from the group consist of methoxy-acrylates, oximino-acetamides, oximino-acetates, oxazolidine-diones, imidazolinones and dihydro-dioxazines;II) Amino Acid and Protein Synthesis and belonging to one of the following sub-groups:methionine biosynthesis (cgs gene) (prop.) which are aniline-pyrimidines (AP) fungicides;
protein synthesis which are hexopyranosyl antibiotics;
protein synthesis which are glucopyranosyl antibiotics; or
protein synthesis which are tetracycline antibiotics; orIII) Sterol Biosynthesis in membranes and belonging to one of the following sub-groups:C14-demethylase in sterol biosynthesis (erg11/cyp51) which are DeMethylation Inhibitors (DMI-fungicides) belonging to the Sterol Biosynthesis Inhibitor (SBI) Class I;
?14-reductase and ?8??7-isomerase in sterol biosynthesis (erg2, erg 24) which are amines “morpholines” belonging to the SBI Class II;
3-Keto reductase in C4-de-methylatin (erg 27) which are belonging to the SBI:Class III; or
squalene epoxidase in sterol biosynthesis (erg1) which are belonging to the SBI class IV.
US Pat. No. 10,137,154

METHODS AND COMPOSITIONS FOR EXPANDING LONG-TERM HEMATOPOIETIC STEM CELL POPULATIONS

BioVentures, LLC, Little...

1. A method of expanding an isolated population of hematopoietic stem cells (HSCs) comprising:a) culturing a starter cell population of HSCs;
b) adding M2 polarized macrophages and optionally at least one macrophage-derived secretion factor to the starter cell population to form an expanding HSC population; and,
c) culturing the expanding HSC population to form an expanded HSC population, wherein the number of long term expanded HSCs is increased in comparison to the number of long term HSCs in the starter cell population, wherein the HSCs have improved expansion and engraftment capabilities compared to HSCs expanded with non-polarized macrophages.
US Pat. No. 10,137,666

NOISE ABSORBENT FABRIC HAVING IMPROVED HEAT AND SOUND INSULATION PROPERTY AND METHOD FOR MANUFACTURING THE SAME

Hyundai Motor Company, S...

1. A noise-absorbent fabric comprising:a metal film; and
a noise-absorbing layer comprising a nonwoven fabric comprising i) an amount of about 30-100 wt % of a heat-resistant fiber based on the total weight of the noise-absorbing layer and ii) a first binder,
wherein the nonwoven fabric comprises microcavities.
US Pat. No. 10,137,155

COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC ANTIGENS

The Trustees of Columbia ...

1. A method of treating a hematopoietic malignancy, comprising administering to a subject in need thereof:(i) an effective amount of an agent targeting a lineage-specific cell-surface antigen, wherein the agent comprises an antigen-binding fragment that binds the lineage-specific cell-surface antigen, wherein the lineage-specific cell-surface antigen is CD33 or CD19; and wherein the agent is an immune cell expressing a chimeric receptor that comprises the antigen-binding fragment; and
(ii) a population of hematopoietic cells, wherein the hematopoietic cells are genetically-engineered such that the gene encoding the lineage specific cell-surface antigen that is targeted by the antigen-binding fragment of (i) is engineered to reduce or eliminate the expression of the lineage-specific cell-surface antigen that is targeted by the antigen-binding fragment of (i); andwherein the immune cell set forth in (i) is different from the population of hematopoietic cells set forth in (ii).
US Pat. No. 10,138,179

METHOD FOR PRODUCING 2,4-DIENAL ACETAL COMPOUND AND 2,4-DIENAL COMPOUND

SHIN-ETSU CHEMICAL CO., L...

1. A method for producing a 2,4-dienal acetal compound of Formula (2):R1CH?CH—CH?CH—CH(OR2)(OR3)  (2),
comprising a step of subjecting a 2-enal acetal compound having a leaving group X at position C5 and being expressed by Formula (1):
R1CHX—CH2—CH?CH—CH(OR2)(OR3)  (1),
wherein, R1 stands for a hydrogen atom or a substituted or unsubstituted monovalent hydrocarbon group having from 1 to 13 carbon atoms, R2 and R3 each independently stands for a monovalent hydrocarbon group having from 1 to 10 carbon atoms, or R2 and R3 are joined together to form, as R2-R3, a divalent hydrocarbon group having from 2 to 10 carbon atoms, X stands for a leaving group which is an alkoxy group having from 1 to 12 carbon atoms, an acyloxy group having from 1 to 10 carbon atoms, a silyloxy group having from 3 to 20 carbon atoms, an alkanesulfonyloxy group having from 1 to 10 carbon atoms, an arenesulfonyloxy group having from 6 to 20 carbon atoms, or a halogen atom,
to an elimination reaction in the presence of a base to obtain the 2,4-dienal acetal compound (2).
US Pat. No. 10,136,900

PNEUMATIC TOURNIQUET

M.A.S. MED GLOBAL LTD, R...

1. An intelligent pneumatic tourniquet, comprising:a) a control device which is locally attached to an inflatable strap having an internal cavity, for achieving a predetermined pressure within said cavity and for thereby applying a required hemorrhage suppressing force onto a limb with which said strap is engaged, wherein said control device comprises a compressed gas container, a flow control unit that is in fluid communication with said container and with said internal cavity, and a rigid housing within which said compressed gas container and said flow control unit are retained; and
b) a strap restraining unit for triggering said flow control unit by an initiating force applied thereby, wherein said flow control unit, when triggered, is configured to selectively supply a dose of pressurized gas discharged from said gas container to said internal cavity,
wherein said flow control unit comprises a slidable puncture pin carrier and an abutment protruding from said carrier, a triggering force being transmitted from said abutment to said carrier to initiate puncturing of a membrane of said compressed gas container and resulting discharge of said compressed gas into said internal cavity of said strap.
US Pat. No. 10,138,180

PRODUCTION OF STYRENE

BADGER LICENSING LLC, Bo...

1. A process for producing styrene, the process comprising:(a) alkylating benzene with ethylene to produce ethylbenzene;
(b) dehydrogenating at least part of the ethylbenzene from (a) to produce a dehydrogenation effluent comprising styrene, together with benzene and toluene as by-products;
(c) separating a fraction containing benzene, toluene and water from the dehydrogenation effluent without prior fractionation to remove the toluene, wherein said fraction contains in excess of 2 ppm by weight of basic nitrogen impurities;
(d) passing at least part of the benzene, toluene and water-containing fraction through a bed of an adsorbent comprising at least one of an acidic clay, and an acidic ion exchange resin to remove basic nitrogenous impurities therefrom and produce a purified benzene, toluene and water-containing fraction containing less than 50 ppb by weight of basic nitrogen impurities; and
(e) recycling a purified benzene fraction to the alkylating (a).
US Pat. No. 10,136,645

ANTIMICROBIAL COMPOSITION

1. An antimicrobial composition comprising:a) Lauric arginate ethyl ester;
b) hydrogen peroxide; and
c) a sequestering agent.
US Pat. No. 10,137,157

TREATMENT OF OBESITY, THE METABOLIC SYNDROME, TYPE 2 DIABETES, CARDIOVASCULAR DISEASES, DEMENTIA, ALZHEIMER'S DISEASE AND INFLAMMATORY BOWEL DISEASE BY USING AT LEAST ONE BACTERIAL STRAIN FROM PREVOTELLA

PROPREV AB, Helsingborg ...

1. A product selected from the group consisting of a food product, food ingredient, food supplement or medicament, said product comprising isolated Prevotella copri (P. copri) and at least one type of dietary fibre,wherein the food product, food ingredient and food supplement are suitable for ingestion and the medicament is suitable for use as a suppository or enema or enclosed in a capsule.
US Pat. No. 10,138,181

METHOD FOR CHLORINATION AND DEHYDROGENATION OF ETHANE

ZHONGKE YIGONG (XIAMEN) C...

1. A method for chlorination and dehydrogenation of ethane, comprising:mixing a low-melting-point metal chloride in a gas phase with C2H6 at a reaction temperature;
reducing the low-melting-point metal chloride to form a liquid-state low-melting-point metal; and
chlorinating and dehydrogenizing the C2H6 to produce a mixed gas containing HCl, C2H6, C2H4, C2H2, and C2H3Cl.
US Pat. No. 10,138,438

LOW SULFUR MARINE DISTILLATE FUEL TRUNK PISTON ENGINE OIL COMPOSITION

Chevron Oronite Technolog...

1. A marine distillate fuel trunk piston diesel engine lubricating oil composition comprising:(a) a major amount of a Group I base oil;
(b) a detergent composition comprising:
(i) a medium overbased detergent comprising an overbased salt of a linear alkyl-substituted hydroxybenzoic acid, wherein at least 90 mole % of the alkyl groups are C20 or greater, and wherein the TBN of the medium overbased detergent on an actives basis is from about 100 to 300 mg KOH/g;
(ii) a high overbased detergent comprising an overbased salt of a linear alkyl-substituted hydroxybenzoic acid, wherein at least 90 mole % of the alkyl groups are C20 or greater, and wherein the TBN of the high overbased detergent on an actives basis is greater than about 300 mg KOH/g; and
(iii) a non-overbased sulfurized alkylphenate detergent which is substantially free of polyol promoter oxidation products; and which is prepared by the process comprising: contacting an alkylphenol having at least one alkyl substituent from 6 to 36 carbon atoms with sulfur, in the presence of a promoter acid selected from the group of alkanoic acids having 1 through 3 carbon atoms, mixtures of the alkanoic acids, alkaline earth metal salts of the alkanoic acids and mixtures thereof, and at least a stoichiometric amount of a calcium base sufficient to neutralize the alkylphenol and the promoter at a temperature of from about 130° C. to about 250° C. under reactive conditions in the absence of a polyol promoter or an alkanol having 1 to 5 carbon atoms for a sufficient period of time to react essentially all of the sulfur thereby yielding a calcium sulfurized alkylphenate essentially free of elemental sulfur, wherein the non-overbased sulfurized alkylphenate detergent is present at less than 3.5 wt %,
wherein the ratio of weight % medium overbased detergent (i) to weight % high overbased detergent (ii) is from about 0.1:1 to 10:1; and
(c) a marine distillate fuel trunk piston diesel engine lubricating oil composition additive selected from the group consisting of an antioxidant, ashless dispersant, other detergent, rust inhibitor, dehazing agent, demulsifying agent, pour point depressant, antifoaming agent, co-solvent, corrosion-inhibitor, dyes, extreme pressure agent and mixtures thereof,
wherein the TBN of the composition is less than 30 mg KOH/g; and
wherein the composition does not contain a friction modifier and an overbased detergent comprising a salt of an alkyl-substituted hydroxybenzoic acid having at least 50 mole % of alkyl groups that are C14-C18.
US Pat. No. 10,136,646

AGRICULTURAL ENDOPHYTE-PLANT COMPOSITIONS, AND METHODS OF USE

Indigo Ag, Inc., Boston,...

1. A method for preparing an agricultural seed preparation, comprising:a) manually or mechanically inoculating a plurality of Glycine agricultural plant seeds with a formulation comprising a purified bacterial population at a concentration of at least 104 CFU/ml in a liquid formulation or at least 104 CFU/gm in a non-liquid formulation, the bacterial population comprising a seed bacterial endophyte comprising a 16S nucleic acid sequence comprising SEQ ID NO: 1446 and exhibiting the ability to produce or induce in a Glycine agricultural plant grown from the inoculated Glycine agricultural plant seed at least one of production of an auxin or production of acetoin, wherein the inoculated seeds and/or the Glycine agricultural plant grown therefrom comprises an increased production of a polypeptide of Aspartate aminotransferase glyoxysomal isozyme AAT1 precursor, wherein the seed bacterial endophyte is present in the formulation in an amount capable of providing a benefit to the inoculated Glycine plant seeds or to the Glycine agricultural plants grown from the inoculated Glycine plant seeds compared to reference Glycine seeds or reference Glycine agricultural plants, wherein the formulation further comprises a stabilizer, a fungicide, a preservative, or a combination thereof; and
(b) packaging the inoculated seeds in a container.
US Pat. No. 10,137,158

USE OF PHOTOSYNTHESIS TO REBALANCE ISCHEMIA BIOENERGETICS

The Board of Trustees of ...

5. A method for correction of a metabolic imbalance as a result of ischemia in a mammalian tissue, the method comprising:contacting a tissue suffering from ischemia or at risk of ischemia with effective dose of photosynthetic microorganisms in the presence of a light source, where the dose or concentration is sufficient to increase oxygenation and simple sugar delivery at the targeted tissue or organ, wherein the tissue is cardiac tissue that is ischemic as the result of a surgical procedure, wherein the tissue is contacted with an effective dose of photosynthetic microorganisms systemically administered in vivo.
US Pat. No. 10,137,670

ACOUSTIC MATERIAL AND MUSICAL INSTRUMENT

Yamaha Corporation, Hama...

1. An acoustic material comprising a plurality of wood veneers laminated via an adhesive,wherein
the veneer is impregnated with the adhesive,
adjacent veneers are substantially in contact with one another, and
the adjacent veneers are impregnated with the adhesive in an amount of no less than 1 g/m2 and no greater than 50 g/m2 per unit area in and around a boundary region of the adjacent veneers.
US Pat. No. 10,141,517

CHARGE-TRANSPORTING MATERIAL

NISSAN CHEMICAL INDUSTRIE...

1. A charge-transporting material comprising:a charge transporting substance:
a halotetracyanoquinodimethane:
a complexing agent having the ability to form a complex with the halotetracyanoquinodimethane, wherein the halotetracyanoquinodimethane and the complexing agent form a complex: and
a heteropolyacid.
US Pat. No. 10,136,647

SYNERGISTIC BACILLUS THURINGIENSIS SUBSP. KURSTAKI AND CHLORANTRANILIPROLE MIXTURES FOR DIAMONDBACK MOTH, BEET ARMYWORM, SUGARCANE BORER, SOYBEAN LOOPER AND CORN EARWORM CONTROL

VALENT BIOSCIENCES LLC, ...

1. A method of controlling a crop plant pest selected from the group consisting of Diamondback moth (Plutella xylostella), Beet armyworm (Spodoptera exigua), Sugarcane borer (Diatraea saccharalis), and Corn earworm (Helicoverpa zea) comprising applying a pesticidally effective amount of Bacillus thuringiensis subsp. kurstaki and chlorantraniliprole to a plant, wherein Bacillus thuringiensis subsp. kurstaki and chlorantraniliprole are applied at a weight ratio of about 1:0.001.
US Pat. No. 10,137,159

BOEHMERIA EXTRACT AND ITS USE IN TREATING LIVER DISEASES

Industrial Technology Res...

1. A method for treating liver fibrosis, the method comprising:identifying a subject suffering from liver fibrosis;
providing a pharmaceutically active extract obtained from Boehmeria nivea; and
administering an effective amount of the pharmaceutically active extract to the subject,wherein the pharmaceutically active extract is obtained by immersing a root of the Boehmeria nivea in water at 25° C.-40° C., removing the root to obtain a solution, and concentrating the solution to form the pharmaceutically active extract; and the pharmaceutically active extract is the only extract from Boehmeria nivea that is administered to the subject.
US Pat. No. 10,138,440

SHOCK ABSORBER OIL COMPOSITION

IDEMITSU KOSAN CO., LTD.,...

1. A method, comprising absorbing vibrations with a shock absorber, said shock absorber comprising a shock absorber oil composition comprising:a base oil:
0. 1 mass % to 1 mass % of a component (A) comprising at least one selected from the group consisting of an acidic phosphate of phosphoric acid and lauryl alcohol, an acidic phosphate of phosphoric acid and oleyl alcohol, an amine salt of acidic phosphate of phosphoric acid and lauryl alcohol, an amine salt of acidic phosphate of phosphoric acid and oleyl alcohol, a phosphite of phosphorous acid and lauryl alcohol, a phosphite of phosphorous acid and oleyl alcohol, an amine salt of the phosphite of phosphorous acid and lauryl alcohol, and an amine salt of the phosphite of phosphorous acid and oleyl alcohol, based on a total amount of the shock absorber oil composition;
0.1 mass % to 1 mass % of a component (B) that is stearic acid amide, based on the total amount of the shock absorber oil composition; and
0.01 mass % to 0.1 mass % of a component (C) that is at least one primary amine selected from the group consisting of monooleyl amine and monolauryl amine, based on the total amount of the shock absorber oil composition,
wherein:
the primary amine (C) is the only amine in the shock absorber oil composition;
the shock absorber oil composition does not contain an ?-olefin copolymer; and
during the absorbing, the high speed friction coefficient between the metals of the shock absorber at a speed of 10 mm/s ranges from 0.108 to 0.112, the low-speed friction coefficient between metals of the shock absorber at a speed of 0.3 mm/s ranges from 0.091 to 0.097, and the ratio between the low-speed friction coefficient to the high-speed friction coefficient ranges from 0.843 to 0.873.
US Pat. No. 10,136,648

FISH ATTRACTION COMPOSITION

1. A fish attractant comprising:a) one or more polyethylene glycol polymers having a mw of about 300 to 4600 in an amount of 19% to 53% by weight of said fish attractant;
b) a polyethylene wax having a mw of about 220 to 560 in an amount of about 7% to 22% by weight of said fish attractant;
c) petroleum jelly in an amount of about 8% about 24% by weight of said fish attractant;
d) a scent in an amount sufficient to attract fish when immersed in water.
US Pat. No. 10,137,160

USE OF HUMULUS JAPONICUS EXTRACT FOR TREATING OBESITY OR HYPERLIPIDEMIA

1. A method for treating obesity or hyperlipidemia in a male subject in need thereof, the method comprising administering an effective amount of a Humulus japonicus extract to said male subject,wherein the Humulus japonicas extract is a water extract or an ethanol extract.
US Pat. No. 10,138,184

CONTINUOUS PROCESS FOR PREPARING ETHYLENE GLYCOL FROM A CARBOHYDRATE SOURCE

Avantium Knowledge Centre...

1. Continuous process for preparing ethylene glycol from a carbohydrate source byreaction of the carbohydrate source with hydrogen,
wherein hydrogen, the carbohydrate source and a liquid diluent are continuously fed into a continuous stirred tank reactor wherein a catalyst system is present, which catalyst system comprises a tungsten compound and at least one hydrogenolysis metal selected from the groups 8, 9 or 10 of the Periodic Table of the Elements, to achieve the reaction between the carbohydrate source and hydrogen to ethylene glycol;
wherein continuously a product mixture comprising ethylene glycol and diluent is removed from the continuous stirred tank reactor; and
wherein continuously or periodically further at least a tungsten compound is added to the continuous stirred tank reactor (CSTR), wherein the amount of tungsten that is added to the CSTR is such that the concentration thereof in the CSTR is substantially constant.
US Pat. No. 10,138,441

FRAGRANCE COMPOSITIONS AND USES THEREOF

1. A composition comprising:(i) a fragrance component present in an amount of from about 0.04 wt % to about 30 wt %, relative to the total weight of the composition, and wherein the fragrance component comprises:
(a) methyl jasmonate present in an amount of from about 10 wt % to about 30 wt %, relative to the total weight of the fragrance component;
(b) ethyl phenyl acetate present in an amount of from about 40 wt % to about 80 wt %, relative to the total weight of the fragrance component; and
(c) ethyl butyrate present in an amount of from about 1 wt % to about 30 wt %, relative to the total weight of the fragrance component;
(ii) undecyl glucoside present in the amount of from about 0.1 wt % to about 20 wt %, relative to the total weight of the composition;
(iii) a volatile solvent present in an amount of from about 50 wt % to about 80 wt %, relative to the total weight of the composition; and
(iv) optionally water.
US Pat. No. 10,136,649

METHODS FOR SCREENING BACTERIA, ARCHAEA, ALGAE, AND YEAST USING CRISPR NUCLEIC ACIDS

North Carolina State Univ...

1. A method of killing a wild-type bacterial cell having a functional endogenous Cascade-Cas3 CRISPR system within a population of bacterial cells, comprising:introducing into the population of bacterial cells a heterologous nucleic acid construct comprising a Cascade-Cas3 CRISPR array (crRNA, crDNA) comprising (5? to 3?) a repeat-spacer-repeat sequence or a repeat-spacer sequence,
wherein the spacer of said repeat-spacer-repeat sequence or said repeat-spacer sequence comprises a nucleotide sequence that is 100% complementary to a target sequence of the wild-type bacterial cell, the target sequence having at least 10 consecutive nucleotides adjacent to a protospacer-adjacent motif (PAM) recognized by the functional endogenous Cascade-Cas3 CRISPR system,
thereby killing the wild-type bacterial cell within the population of bacterial cells;
provided that the following are not introduced into the population of bacterial cells:
(a) an exogenous Cas3 polypeptide that recognizes a complex of Cascade and the Cascade-Cas3 CRISPR array, and an exogenous nucleic acid construct encoding said exogenous Cas3 polypeptide; and
(b) an exogenous Cascade polypeptide that recognizes the Cascade-Cas3 CRISPR array, and an exogenous nucleic acid construct encoding said Cascade polypeptide.
US Pat. No. 10,138,185

METHOD FOR PREPARATION OF MANNITOL FROM FRUCTOSE USING BUTANOL AS SOLVENT

Korea Research Institute ...

1. A method for preparing mannitol, comprising performing hydrogenation of fructose in the presence of a nanocomposite catalyst of CuO(x)/SiO2(100-x) (wherein x is a real number from 20 to 90) using butanol as a solvent.
US Pat. No. 10,138,442

OUTDOOR CLEANING SYSTEM CONCENTRATES

Jelmar, LLC, Skokie, IL ...

1. An outdoor cleaning concentrate composition comprising:a surfactant selected from the group consisting of alkyl glucosides, alkyl carboxylates, alkyl polyoxyethylenes, alkyl polysaccharides, alkylamine ethoxylates, amphoterics, amine oxides, polyalkylene glycol, sarcosines and sarcosinates;
a fungicide, comprising about 6 wt. % to about 12 wt. % of the composition;
a chelating agent; and
a disinfectant comprising potassium carbonate,
wherein the pH of the concentrate composition ranges from about 9.4 to about 9.8.
US Pat. No. 10,137,162

GASTROPROTECTIVE EXTRACTS OF SONCHUS OLERACEUS L.

King Saud University, Ri...

1. A method of producing gastroprotective extracts of Sonchus (S.) oleraceus L., comprising the steps of:selecting a source material consisting of S. oleraceus L. roots;
grinding the source material into a powder to produce 500 grams of powder;
extracting the powder by percolation in 2 liters of 95% aqueous ethanol for 2 days at room temperature to produce an ethanol extract;
concentrating the ethanol extract in a rotary evaporator at a temperature of less than 25° C. to form a residue;
suspending the residue in distilled water until it is dissolved;
filtering the dissolved residue to produce an aqueous filtrate;
collecting any lipoidal matter trapped on a filter;
further extracting a portion of the aqueous filtrate to exhaustion in chloroform;
drying the chloroform extracts at a temperature less than 20° C.;
further extracting the aqueous filtrate to exhaustion with n-butanol; and
drying the n-butanol extracts at a temperature less than 35° C.; recovering the gastroprotective extracts of S. oleraceus L.
US Pat. No. 10,137,418

COMPOSITE POLYAMIDE MEMBRANE MADE VIA INTERFACIAL POLYMERIZATION USING A BLEND OF NON-POLAR SOLVENTS

DOW GLOBAL TECHNOLOGIES L...

1. A method for making a composite polyamide membrane comprising a porous support and a thin film polyamide layer, wherein the method comprises:i) applying a polar solution comprising 2.5 to 6 wt % m-phenylene amine and a non-polar solution comprising 0.05 to 0.3 wt % trimesoyl chloride to a surface of a porous support and interfacially polymerizing the monomers to form a thin film polyamide layer,
wherein the non-polar solution comprises:
a) 50 to 90 vol % of C5 to C20 aliphatic hydrocarbon selected from a paraffin or isoparaffin, or combination thereof,
b) 3 to 15 vol % mesitylene, and
c) 0.02 to 0.08 wt % 1-carboxy-3,5-dichloroformyl benzene (mhTMC); and
ii) applying an aqueous solution of nitrous acid to the thin film polyamide layer.
US Pat. No. 10,138,186

PROCESS FOR MAKING BIOBASED PROPYLENE GLYCOL FROM LACTIC ACID ESTERS

Archer Daniels Midland Co...

1. A process for making a biobased propylene glycol product at least in part from a carbohydrate-derived feed, comprising reacting a feed comprised of propylene glycol lactic acid ester with hydrogen in propylene glycol in the presence of a catalyst, in a liquid phase reaction.
US Pat. No. 10,138,443

CLEANING COMPOSITION WITH RAPID FOAM COLLAPSE

Rohm and Haas Company, P...

1. An aqueous foaming cleaning composition comprising:a nonionic alkoxylated surfactant that is a condensation product of an alcohol having a 2-ethyl hexyl group and 2 to 9 moles of ethylene oxide and propylene oxide per molecule of the alcohol, wherein the nonionic surfactant has a hydrophilic-lipophilic balance of 8.5 to 13.5;
a first compound comprising ethyl octanoate, butyl octanoate, ethyl decanoate, butyl decanoate, ethyl laurate, or a combination thereof; and
a second compound that is miscible with water and has Hansen solubility parameters of 14 MPa0.5??D?17 MPa0.5, 1??P?7 MPa0.5, and 7??H?12 MPa0.5,
wherein the surfactant, the first compound, and the second compound are each independently included in an amount of 0.2 to 8 weight percent, based on a total weight of the cleaning composition.
US Pat. No. 10,136,651

DE-OILED SABADILLA EXTRACT

MCLAUGHLIN GORMLEY KING C...

1. A method for producing a de-oiled sabadilla extract consisting essentially of: milling sabadilla seeds with cryogenic hammer milling;washing the milled sabadilla seeds with at least one extract solvent selected from the group consisting of chlorinated methane, chlorinated ethane, and benzene, under agitation to dissolve the sabadilla oil in the extract solvent; and
removing the extract solvent and sabadilla oil to yield the de-oiled sabadilla extract.
US Pat. No. 10,137,163

MELALEUCA QUINQUENERVIA EXTRACTS AND USES OF THE SAME

TAIWAN SUGAR CORPORATION,...

1. A method for inhibiting Wnt/?-catenin signal transduction pathway in a subject comprising administering to the subject in need an effective amount of a Melaleuca quinquenervia extract, wherein the extract is prepared by a method comprising the following steps:(a) extracting Melaleuca quinquenervia with a second polar solvent to provide a first extraction fluid, wherein the second polar solvent is methanol, water, or a combination thereof;
(b1?) partitioning the first extraction fluid with a C5-C8 alkane and removing the alkane phase;
(b2?) partitioning the product of step (b1?) with ethyl acetate and removing the ethyl acetate phase;
(b) partitioning the product of step (b2?) with a first polar solvent and collecting the first polar solvent phase, wherein the first polar solvent is a C3-C6 alcohol; and
(c) optionally removing the first polar solvent from the first polar solvent phase.
US Pat. No. 10,138,187

PROCESS FOR THE SYNTHESIS OF 9,9-BIS(HYDROXYMETHYL)FLUORENE

SABIC GLOBAL TECHNOLOGIES...

1. A process for the synthesis of 9,9-bis(hydroxymethyl)fluorene from fluorene comprising providing a mixture of paraformaldehyde, dimethylsulfoxide and a sodium alkoxide and adding fluorene to said mixture to obtain 9,9-bis(hydroxymethyl)fluorene, wherein fluorene is added as a solid.
US Pat. No. 10,138,444

BACTERIA AND ENZYMES PRODUCED THEREFROM AND METHODS OF USING SAME

Agri-King, Inc., Fulton,...

1. A method of producing a composition capable of degrading at least one polysaccharide, the method comprising,a) culturing strain Bacillus subtilis 6A-1 (6A-1), reference culture comprising said 6A-1 having been deposited at ATCC under deposit number PTA-125135, such that said 6A-1 produces at least two polysaccharide-degrading protein fractions;
b) a process selected from (i) filtering or drying or freeze drying or grinding, or adding at least one excipient, carrier or diluent to said 6A-1 strain or cells or spores of said 6A-1 or (ii) extracting at least one polysaccharide-degrading protein fraction from said 6A-1, or iii) a combination thereof and
c) producing a composition comprising said strain, cells, spores or at least one polysaccharide-degrading protein fraction extraction of b), or a combination thereof.
US Pat. No. 10,139,727

CHEMICAL AMPLIFICATION RESIST COMPOSITION, RESIST FILM USING THE SAME, RESIST-COATED MASK BLANK, METHOD OF FORMING PHOTOMASK AND PATTERN, AND METHOD OF MANUFACTURING ELECTRONIC DEVICE AND ELECTRONIC DEVICE

FUJIFILM Corporation, To...

1. A chemical amplification resist composition comprising:(A) a compound including a triarylsulfonium cation having two or more fluorine atoms and capable of generating an acid with a volume of 240 ?3 or higher by irradiation of active rays or radiation;
(B) a compound including a phenolic hydroxyl group; and
(C) an acid crosslinking compound,
wherein benzene rings configuring at least two aryl groups from the three aryl groups in the triarylsulfonium cation of the compound (A) each independently is directly bonded to at least one fluorine atom, and
the compound (B) is a resin having a weight average molecular weight of 2,000 or more.
US Pat. No. 10,136,652

PLANT-BASED COMPOSITIONS AND USES THEREOF

GreenStract, LLC, Spring...

1. A method for inhibiting growth of bacteria, fungi or a virus on a substrate, comprising contacting the substrate with an aqueous composition, wherein the aqueous composition comprises:a mixture obtained by (a) allowing water, plant material and an inorganic base to (i) stir at about 10° C. to about 100° C. for about 2 hours to about 4 hours or (ii) stand at about 10° C. to about 100° C. for about 10 minutes to about 8 hours, and (b) removing undissolved solids from the mixture;
0% to about 10 wt % of an alcohol;
about 0.5% to about 15 wt % of the inorganic base;
0% to about 10 wt % of a salt;
0% to about 10 wt % of an acid;
0% to about 10 wt % of an additive; and
about 10 wt % to about 95 wt % of water;whereinthe aqueous composition has a pH of about 13;
the amount of plant material is from about 1 wt % to about 50 wt % of the aqueous composition;
the plant material is corn gluten meal; and
the substrate is soil, sand, wood, rock, paper, skin, a water body, gravel, mud, clay, plant, hair, fabric, metal, glass, porcelain, plastic, concrete, a living animal or a dead animal.
US Pat. No. 10,137,164

DIETARY SUPPLEMENT COMPOSITIONS

Melaleuca, Inc., Idaho F...

1. A composition consisting essentially of:(a) between about 0.01 and about 0.40 mg of huperzine A,
(b) between about 200 mg and about 3000 mg of acetyl-L-carnitine,
(c) between about 50 mg to about 1000 mg of Bacopa monnieri,
(d) between about 25 mg and about 400 mg of curcumin,
(e) between about 100 IU and about 800 IU of Vitamin E,
(f) between about 0.1 mg and about 10 mg of folic acid, and
(g) between about 0.006 mg and about 2.5 mg of Vitamin B12;
wherein said composition is in the form of a tablet or capsule.
US Pat. No. 10,139,728

METHOD FOR MICROWAVE PROCESSING OF PHOTOSENSITIVE POLYIMIDES

APPLIED MATERIALS, INC., ...

8. A method for curing photopolymer films, comprising:depositing a photopolymer film on a substrate;
photopatterning the photopolymer film;
developing the photopatterned photopolymer film; and
curing the developed photopolymer film by microwave heating for a selected time in a selected atmosphere containing an oxygen concentration from about 20 to 200,000 ppm, wherein the oxygen concentration is maintained by at least one of supplying a known amount of oxygen gas to the atmosphere or adjusting the pressure of the atmosphere.
US Pat. No. 10,136,653

METHOD FOR IMPROVING BRAN AND GERM FLAVOR AND TEXTURE

Intercontinental Great Br...

1. A method for improving the flavor and texture of a ground bran and germ component comprising:subjecting a ground bran and germ component to heating while conveying and mixing the ground bran and germ component in a conveying and mixing device, said ground bran and germ component comprising bran and germ having at least 50% by weight bran and a moisture content of from about 5% by weight to about 12% by weight, based upon the weight of the ground bran and germ component, said heating being to a temperature of from about 290° F. to about 430° F. and being conducted for a period of time of from about 1 minute to about 6 minutes to volatilize volatile wheaty flavor components and moisture in the ground bran and germ component, to develop a buttery, nutty, caramelized flavor in the bran component, and to reduce lipase activity of the bran and germ component,
removing the wheaty flavor components and moisture from the mixing and conveying device by venting during said heating to reduce the moisture content of the bran and germ component by about 30% by weight to about 75% by weight and to obtain a dried ground bran and germ component having a moisture content of from about 1.5% by weight to about 4.5% by weight, and
removing the dried ground bran and germ component from the conveying and mixing device to obtain a non-expanded stabilized ground bran and germ component having a non-wheaty, nutty, caramelized flavor and a non-gritty texture,
wherein the bran and germ component comprises starch, and said heating avoids gelatinization of starch contained in the bran and germ component such that starch gelatinization is less than about 25%.
US Pat. No. 10,138,446

CLEANING PRODUCT

1. A cleaning product comprising a spray dispenser and a cleaning composition suitable for spraying and foaming, the composition housed in the spray dispenser wherein the composition comprises:i) about 2 to about 15% by weight of a surfactant system comprising an alkyl ethoxylated sulfate anionic surfactant and a co-surfactant selected from the group consisting of amphoteric surfactant, zwitteronic surfactant and mixtures thereof;
ii) a glycol ether solvent selected from the group consisting of glycol ethers of Formula I: R1O(R2O)nR3, Formula II: R4O(R5O)nR6 and mixtures thereof wherein
R1 is a linear or branched C4, C5 or C6 alkyl, a substituted or unsubstituted phenyl,
R2 is ethyl or isopropyl, R3 is hydrogen or methyl and n is 1, 2 or 3
R4 is n-propyl or isopropyl, R5 is isopropyl, R6 is hydrogen or methyl and n is 1, 2 or 3;
iii) bicarbonate; and
iv) an alkanol amine.
US Pat. No. 10,137,166

COMPOSITIONS AND METHODS FOR AFFECTING MOVEMENT OF CONTAMINANTS, BODILY FLUIDS OR OTHER ENTITIES, AND/OR AFFECTING OTHER PHYSIOLOGICAL CONDITIONS

Massachusetts Institute o...

1. A composition for making an in vivo barrier structure, comprising self-assembling peptidomimetics, comprising between 6-64 alternating hydrophobic and hydrophilic residues,wherein the hydrophilic residues alternate between positively-charged and negatively-charged residues,
wherein the self-assembling peptidomimetics are copolymers of two or more selected from the group consisting of ?-peptides, ?-peptides,?-peptides, and ?-peptides,
wherein the self-assembling peptidomimetics are able, upon interaction with at least one ionic species present at a site of a wound or injury or surgery on or in a subject, to form a structure that inhibits movement of a bodily fluid and/or contaminant of the subject.
US Pat. No. 10,138,447

FRAGRANCE INTENSITY ENHANCED PRODUCTS AND METHODS THEREFOR

Colgate-Palmolive Company...

1. A product container comprising:a lid, cap or cover,
a product comprising a first fragrance; and
a fragrance-containing gel comprising a second fragrance,
wherein the fragrance-containing gel is disposed on an interior surface of the lid, cap or cover and is not exposed to a space outside of the product container until the lid, cap or cover is at least partially removed;
wherein the concentration of the second fragrance in the fragrance-containing gel is greater than the concentration of the first fragrance in the product; and
wherein the fragrance-containing gel contains 85 to 95 weight % of the second fragrance and is present on the interior surface of the lid, cap or cover in an amount of 0.02 to 0.2 g.
US Pat. No. 10,137,167

METHODS COMPRISING DESMOPRESSIN

Ferring B.V., Hoofddorp ...

1. A method of further reducing nocturnal voids in a male patient in need thereof comprising:measuring the patient's serum sodium level;
administering to the patient, with a serum sodium level of at least 130 mmol/L, prior to bedtime an orodispersible dose of desmopressin chosen from 25 ?g, 50 ?g, and 100 ?g over a first treatment period of about 28 days, wherein the dose is taken from 0.8 to 3 hours prior to the patient's bedtime and once daily;
measuring the patient's serum sodium level after the first treatment period; and
continuing to administer the orodisperible dose of desmopressin prior to bedtime over a second contiguous treatment period of at least 28 days to about 1 year if the male patient has a serum sodium level of at least 130 mmol/L,
wherein the nocturnal voids over the second treatment period are further reduced in view of the reduction in the nocturnal voids over the first treatment period and wherein the reduction in the nocturnal voids over the first treatment period is determined based on the patient's nocturnal voids before administration of the orodispersible dose of desmopressin for the first treatment period.
US Pat. No. 10,137,168

VETERINARY DECORIN COMPOSITIONS AND USE THEREOF

CATALENT PHARMA SOLUTIONS...

1. A veterinary decorin core protein molecule that is at least 98% identical to one of SEQ ID NOs:4, 7, 10, 13, 16, 19, 22, and 27, wherein the veterinary core protein molecule comprises an aspartic acid residue at the N-terminus and does not comprise a serine residue at the fourth amino acid from the N-terminus.